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VAbstract
A diversity of disease processes and conditions such as Alzheimer´s disease,
schizophrenia, epilepsy and stroke are major pathological conditions at present time.
Although such sufferings are caused by different mechanisms they share the NMDA-
receptor as one common target. The number of reports suggesting the presence of this
glutamate-gated ion-channel at the blood-brain barrier and its participation in major
regulatory mechanisms increased in the last years.
The first goal of this thesis was to confirm and investigate the presence of NMDAR-
subunits NR-1, -2A, -2B, and -2C in human blood-brain barrier cell line ECV304 by
western blot analysis and immunofluorescence microscopy in order to obtain an overview
of possible compositions of a functional NMDA-receptor. Subsequently, it was aimed at
establishing a 96-well plate fluorescence-assay for measuring the intracellular Ca2+-level as
a functional parameter of the activation of the NMDA-receptor. Furthermore, methods as
the measurement of the transendothelial electrical resistance (TEER) and western blotting
were to be performed in order to investigate the influence of overstimulation or inhibition
of the NMDA-receptors on specific blood-brain barrier properties. The presence of all four
investigated NMDA-receptor subunits in the used blood-brain barrier in vitro model was
shown, but their localisation within the cell membrane was not proven which is suggested
to be prerequisite for NMDAR-functionality as a Ca2+-channel. In concordance to this,
Ca2+-level measurements revealed controversial results with NMDAR-agonists. For further
validation of the test system, other intracellular Ca2+-level modulators were additionally
tested which confirmed the suitability of the test set-up. Despite of this, adverse effects of
glutamate onto blood-brain barrier integrity (TEER) were confirmed which were inhibited
by NMDAR-blocker MK801. Moreover, changes in the expression levels of several
specific proteins of samples obtained from the TEER experiments were shown by western
blotting.
Taken together, obtained data confirmed data from the literature on the one hand, but also
suggested possible involvement of additional targets for NMDA-modulators NMDA and
MK801 than the NMDAR on the other hand. With regard to the methods, a 96-well plate
fluorescence assay was established which may be used as a first screening method to find
possible substrates targeting the blood-brain barrier and regulating the intracellular Ca2+-
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level. In the next step, methods as western blotting and TEER measurement could be
applied in order to prove the functional relevance of these intracellular calcium modulating
drug.
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Zusammenfassung
Eine Vielfältigkeit an Krankheitsprozessen und Zustände wie Alzheimer-Krankheit,
Schizophrenie, Epilepsie und Schlaganfall sind bedeutende pathologische Gegebenheiten
in der heutigen Zeit. Obgleich diese Leiden durch verschiedene Mechanismen ausgelöst
werden, teilen diese dennoch den NMDA-Rezeptor als gemeinsames Target. Von einer
Anwesenheit und Beteiligung dieses Glutamat-gesteuerten Ionenkanals wird immer
häufiger bei wichtigen regulatorischen Mechanismen an der Blut-Hirn-Schranke berichtet.
Das erste Ziel dieser Diplomarbeit war die Anwesenheit von NMDA-Rezeptor-
Untereinheiten NR-1, -2A, -2B und -2C in der humanen Blut-Hirn-Schranken Zelllinie
ECV304 durch Western-Blot-Analysen und Immunofluoreszenz-Mikroskopie zu
bestätigen und zu untersuchen, um einen Überblick von möglichen Zusammensetzungen
eines funktionellen NMDA-Rezeptors zu bekommen. Anschließend war die Etablierung
eines 96-Well Plattenfluoreszenz-Assay zum messen des intrazellulären Ca2+-Spiegel,
welcher als funktioneller Parameter einer NMDA-Rezeptoraktivierung gesehen werden
kann, unser Ziel. Darüber hinaus wurden Methoden wie die Messung des
transendothelialen elektrischen Widerstandes (TEER) und Western-Blots durchgeführt, um
den Einfluss einer Überstimulation oder Inhibition des NMDA-Rezeptors auf spezifische
Blut-Hirn-Schranken Eigenschaften zu überprüfen. Die Anwesenheit aller vier
untersuchten NMDA-Rezeptor Untereinheiten konnte in dem verwendeten in vitro Blut-
Hirn-Schranken Model gezeigt, jedoch ihre Lokalisation innerhalb der Zellmembran, was
als Voraussetzung für NMDA-Rezeptorfunktionalität als Ca2+-Kanal vermutet wird, nicht
bewiesen werden. In Übereinstimmung zu diesem zeigten Messungen des Ca2+-Spiegel
Widersprüchliche Ergebnisse mit NMDA-Rezeptor-Agonisten. Für eine weitere
Validierung des Testsystems wurden zusätzlich noch weitere intrazelluläre Ca2+-Spiegel-
Modulatoren getestet, welche die Brauchbarkeit des Testset-ups bestätigten. Trotz allem
konnten ungünstige Effekte von Glutamate auf die Blut-Hirn-Schranken-Integrität (TEER)
gezeigt werden, welche durch den NMDA-Rezeptorblocker MK801 unterbunden wurden.
Darüber hinaus wurden Änderungen im Expressionslevel von einigen bestimmten
Proteinen, welche von Proben aus den TEER-Versuchen gewonnen wurden, mit Hilfe von
Western Blots gezeigt.
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Zusammenfassend bestätigten die gewonnen Resultate einerseits jenen Daten der Literatur,
jedoch auch eine mögliche Beteiligung zusätzlicher Targets für NMDA-Modulatoren wie
NMDA und MK801 als den NMDA-Rezeptor wäre andererseits möglich. In Bezug zu den
Methoden konnte ein 96-Well Plattenfluoreszenz-Assay etabliert werden, welcher
eventuell als erste Vorscreening-Methode zur Findung mögliche Substrate, welche gegen
die Blut-Hirn-Schranke gerichtet sind und den intrazellulären Ca2+-Spiegel regulieren,
verwendet werden kann. Anschließend können Methoden wie Western Blots und TEER-
Messungen angewendet werden, um die funktionelle Bedeutung dieser intrazellulären
kalziummodulierden Substanzen zu überprüfen.
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1 Introduction
The blood-brain barrier (BBB) is an essential protection system to maintain the function of
the central nervous system. Interactions between endothelial cells, astrocytic end-feet,
pericytes and basal membrane primarily induce those special properties which lead to a
functional BBB. With the emerging features and characteristics this barrier is able to
control the supplies of nutrients for the brain and ion gradients as it also prevents
uncontrolled flux of ions, amino acids, peptides and xenobiotics capable of disturbing
neuronal functions [1].
The special constitution and properties of the BBB will be summarized after a short
historical review.
1.1 History of the Blood-Brain Barrier
Before more than 100 years, Paul Ehrlich (1854-1915) injected defined dyes into the
vascular system in 1885, which were quickly taken up by the organs. Only the brain and
the spinal cord had been pictured as a special case where no drugs had been found and
Ehrlich misinterpreted his findings as a lack of affinity of the nervous system for these
dyes [2]. At a later date same dyes had been injected into the cerebrospinal fluid by
Ehrlichs associate Edwin Goldman. He discovered that only the nervous tissues were
stained and something prevented the dyes from gaining access to the blood circulation.
The term „blood-brain barrier“ was first characterised by Lewandowsky. In 1890, he had
performed experiments showing that potassium-hexacyanoferrate (II) only affected brain
function when directly injected into the brain but not when injected into the vascular
system. Nearly at the same time Biedl and Kraus demonstrated the similar effects with bile
acid in the brain. Approximately after further 70 years the capillary endothelial cells within
the brain had been identified as the main component of the „barrier“ by electron-
microscopic studies from Reese and Karnovsky (1967) and Brightman and Reese (1969).
21.2 Components of the Blood-Brain Barrier
1.2.1 Endothelial cells
In contrast to endothelial cells (EC) of the peripheral circulation brain microvascular
endothelial cells (BMEC) (Fig. 1.1) are characterised by structural components called tight
junctions (TJ) [3]. A very small pinocytotic activity, lacks of fenestration and an increased
amount of cytosolic mitochondria are further typical features of the BBB [3, 4]. Moreover
an enzymatic barrier that is capable of metabolizing drugs and nutrients could be found in
?????????????????????????????????????????????????????????????????????????????????????
decarboxylase. The distribution and functionality of a variety of transporters as P-
glycoprotein (P-gP) at the BBB play also an important role in protecting the brain of
possibly harmful xenobiotica.
1.2.2 Astrocytes
Astrocytes (AC) are glial cells that envelop ~99% of the BBB endothelial cells [3].
Generally, astrocytes support neurones with nutrients through contacts to the blood vessel,
since neurons never encounter the bloodstream. Specific characteristics of astrocyte end-
feet are high concentrations of the water channel aquaporin 4 (AQP4) and the K+ channel
Kir4.1, which are important for the fluid regulation in the brain and in the potassium-
household [4].
Moreover, recent in vitro studies showed influence of astrocytes on BMEC, which resulted
in tighter TJ, the expression and polarized localization of transporters as P-gP and GLUT1
and specialized enzyme systems [5, 6]. A few of those studies also showed evidence, that a
direct interaction between endothelial cells and astrocytes was not necessary to induce
BBB properties in BMEC because astrocyte conditioned medium (ACM) alone revealed
similar but weaker beneficial effects.
1.2.3 Pericyte
Pericytes (PC) are cells that cover about 20-30% of endothelial cells from microvessels
including capillaries, venules and arterioles. Their appearance is restricted to every second
3to fourth BMEC, whereby PCs prefer to be close to a contact-spot of two EC. Although
PCs are separated through a basal lamina from BMEC, a direct contact is possible through
gap junctions. It’s been suggested that PC can also influence the regulation of EC
proliferation, survival, migration, differentiation and vascular branching by those contacts
[3]. Under pathological conditions like hypoxia or traumatic brain injury PC can migrate
away from brain microvessels which lead to an increased BBB permeability. Therefore,
probably also PC play a major and beneficial role – similar effects were already seen with
AC – in maintaining the tightness and structural integrity of the BBB [3,7].
Fig. 1.1: Cellular constituents of the blood-brain barrier [5]
41.2.4 Basal lamina
The basal lamina is an about 40-50 nm thick layer of proteins that surrounds the
endothelial cells and pericytes. Moreover, it represents a non-cellular component of the
BBB. Assemble of type IV collagen, fibronectin, laminin and different proteoglycans, the
basal lamina build up some sort of specialized extracellular matrix. Pathological conditions
like ischemic stroke can cause an increased BBB permeability by disappearance of
important components like type IV collagen, fibronectin and laminin [11].
1.3 Physiology of blood-brain barrier junctional complexes
BMEC are connected by a strong cell-cell-association that is characterized by a junctional
complex including adherens junctions (AJ), tight junctions (TJ) and possibly gab junctions
(Fig. 1.2) [7].
1.3.1 Adherens junctions
AJ are protein complexes that occur between cell-cell-associations, mediating adhesion of
vascular EC to each other, contact inhibition during vascular growth and remodelling,
initiation of cell polarity, and some participation in the regulation of paracellular
permeability. The main component of AJ is vascular endothelial cadherin (VE-cadherin),
????????????????????????????????????????????????????????????????????????????????????????ß-
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studies showed that TJ were predominantly responsible for the low paracellular
permeability and a high electrical resistance, a disruption of AJ can also cause an increased
permeability [7].
1.3.2 Tight junctions
As already mentioned, the interactions of TJ–proteins between BMEC primarily play the
important role in the maintenance of BBB tightness. Therefore, this fusion will nearly
5exclude every paracellular transport and force substances to permeate transcellularly
through the membranes and the cytosol (Fig. 1.3).
A few plasma membrane proteins have been identified as TJ proteins such as claudins,
occludin and junctional adhesion molecules (JAM). Those transmembrane TJ-proteins are
linked by cytoplasmatic TJ anchoring proteins like ZO-1, ZO-2, ZO-3 (zonula occludens)
and cingulin to actin [8].
Fig. 1.2: Molecular composition of endothelial thight juncitons [5]
1.3.2.1 Occludin
In 1993, Occludin was the first identified integral membrane protein of the tight junctions.
With his 65 kDa this phosphoprotein is considerably bigger than Claudins [12], moreover
it also shows no sequence similarity to this protein. From the structural point of view
Occludin has four transmembrane domains with a long carboxyl and a short amino
terminal directed to the cytoplasm. Two extracellular loops spanning the intercellular cleft
form together with claudin one part of the paracellular barrier of the BBB. The
6cytoplasmatic C–terminal domain of occludin is directly associated with the cytoplasmatic
anchoring proteins ZO-1 and ZO-2 and provides the connection to the cytoskeleton [7].
Fig. 1.3: Pathways across the BBB [5]
1.3.2.2 Claudins
Since 1998 at least 18 proteins of the claudin – family have been identified in human. All
of those 20–24 kDa phosphoproteins have their own specific sequence. Nevertheless
similar predicted foldings and a high sequence homolgy among the first and fourth
transmembrane domain and their extracellular loops exist [3]. Homophilic and heterophilic
interactions of those extracellular loops provide a tight contact between the cells.
Moreover, it is assumed that claudins are responsible for generating the primary TJ –
connection between each cell, whereas occludin subsequently improve the tightness of TJ
[7]. It is assumed that Claudin–3, Claudin–5 and Claudin-12 are expressed primarily in the
endothelial cells of the BBB.
71.3.2.3 Junctional adhesion molecules (JAM)
Until now the function of junctional adhesion molecules (JAM) in the mature BBB is still
largely unclear. JAM–1, an about 40 kDa protein, is a member of the IgG superfamily. It
consists of single membrane-spanning chains that have a large extracellular domain,
mediate – probably through homophilic interactions – the early attachment of adjacent cell
membranes in the BBB [12].
1.3.2.4 Cytoplasmatic TJ anchoring proteins
Besides transmembrane components of TJ, there are several anchoring proteins, including
zonula occludens (ZO-1, ZO-2, ZO-3), cingulin, AF-6 and others that connect with them in
the cytoplasm [12]. The association with TJ was firstly proven for ZO-1, a 220 kDa
phosphoprotein [7]. It belongs with ZO–2 and ZO–3 to the membrane-associated guanylate
kinase (MAGUK) proteins that are also accessory elements for the transmembranous
components of TJ in the cytoplasm. However, most is known about ZO–1 which connects
the transmembrane proteins of TJ to the actin cytoskeleton – e.g. the C-terminus from
occludin binds over ZO-1 to actin filaments. An increased BBB permeability is also
associated with the dissociation of ZO–1 from the complex of tight junctions with the
cytoskeleton [3].
1.4 Calcium signalling and calcium metabolism
The divalent cation calcium (Ca2+) acts as intracellular second messenger controlling many
essential cellular processes including muscle contraction, secretion, metabolism, neuronal
excitability, cell proliferation and cell death. Former studies on BBB regulation of
tightness and its decrease, demonstrated the importance of this second messenger.
Moreover extracellular Ca2+ depletion and/or an intracellular increase were known to
increase BBB disruption of TJ, even before some of those specific proteins were well
characterized [13].
Two main pathways for Ca2+ signalling in living cells are possible, whereas either an
influx from the extracellular space through channels in the plasma membrane or a release
from internal stores occur. The Ca²+ level of cells at rest are kept between 10–100 nM,
8stimulation lead to increased cytosolic concentrations up to 1 µM or even more [14]. Since
only stimulations will cause cell-damage after a period of time, a counter-regulation is
needed to ensure balance. Such counter-regulations should reduce high Ca2+ concentration
and adjust again to a normal concentration in the nM range. Those “On” and “Off”
mechanism – characterized by the increase or decrease of cytosolic Ca2+ concentrations –
are so coordinated that they produce brief spikes and waves to generate different signals
for cell regulation (figure 1.4).
1.4.1 Ca2+ – “On” mechanism
1.4.1.1 Plasma membrane channels
A diversity of Ca2+ influx channels at the plasma membrane are known that can be grouped
by the way of their activation.
Fig. 1.4: Overview of the “On”- and “Off”-mechanisms and modulations of intracellular calcium level [14]
9Voltage–operated channels (VOC): Depolarization of the plasma membrane triggers a
selective influx of calcium ions into the cell. This family is divided in L-, T-, N-, P/Q- and
R-type channels that vary in the basis of their kinetics and pharmacological properties.
Receptor–operated channels (ROC): This group of receptors like NMDA-receptor or
AMPA-receptor needs specific binding of an agonist whereby the channel opens and a
Ca2+ entry takes place.
Store-operated channels (SOC): These channels were activated when the calcium of the
internal stores deplete. However, the interaction between internal stores with SOC is still
unclear. A communication over a calcium-influx factor (CIF) and/or over direct protein-
protein interactions is assumed.
1.4.1.2 Intracellular Ca2+ channels
Inositol 1, 4, 5-trisphosphate receptors and Ryanodine receptors are those substitutes for
the merging of different signalling pathways. Activation of these channels are possible by
numerous factors like phosphorylation, adenosine-nucleotides, thiol-reactive compounds,
pH and the Ca2+ load of the endoplasmatic reticulum or sarcoplasmatic reticulum (ER/SR)
[9].
Inositol 1, 4, 5-trisphosphate (InsP3) receptor: Specific receptor like G-protein-linked or
tyrosine kinase-linked receptors leads to activation of phospholipase C that produce the
second messenger (InsP3). This messenger diffuses into the cell interior to release stored
Ca2+ from the ER/SR by binding on InsP3 receptors.
Ryanodine receptor (RYR): These receptors have similar structural and functional
properties compared to InsP3 receptors; also their sensitivity to cytosolic Ca
2+
concentrations are related to those, although RYR were generally activated and inhibited
by higher concentrations [9].
1.4.2 Ca2+ – “Off” mechanism
In order to avoid cell damage, an increased cytosolic calcium signal has to be decreased
again through those counter-regulations or so called “Off” mechanism.
Sodium-calcium exchangers are pumps on the surface of the cell membrane that are mainly
expressed in the heart and brain. During each reaction cycle an influx of three sodium ions
was performed while one Ca2+ ion is effluxed. The energy needed for this pump is
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generated by the Na+/ K+ ATPase and the activity of the Na+/ Ca2+ exchanger is dependent
on factors as Na+, Ca2+, intracellular pH and ATP.
The ubiquitous Ca2+-ATPase (PMCA), found on the plasma membrane, is another “Off”
mechanism controlled by a diversity of factors including calmodulin, acidic phospholipids
and protein kinases A and C. Together with the Na+/ Ca2+ exchanger the PMCA is the main
regulator for intracellular down-regulation of calcium concentrations.
Structurally similar to PMCA the uptake from the cytoplasma to the internal stores is
characterized by a sarco/endoplasmatic reticulum Ca2+ ATPase (SERCA).
1.5 The NMDA-receptor
The NMDA receptor is a specific type of ionotropic glutamate receptor. The name is
derived from its selective agonist N–methyl–D–aspartate (NMDA). The majority of the
literature sees the NMDA receptor being present as a key signalling protein with complex
roles in the physiology of the central nervous system (CNS). There this channel is needed
consistently for synapse formation, maintenance and is involved in brain functions like
learning, memory and certain behaviours [10]. More and more studies also reported the
presence of this target in extra-synaptic locations like the spinal cord, osteoblasts,
osteclasts and their progenitors, but their physiological role there is still not clarified. Also
the presence and participation in major regulatory mechanisms at the BBB had been
reported [18, 20, 21].
The importance of this receptor seems to become clear, when someone considers that this
receptor is indispensable to life for normal brain function and probably also other functions
in the body. However, an extra activation or over-stimulation of this target by a diversity of
disease processes and conditions such as Alzheimer’s disease, epilepsy or stroke –
although they are caused by different mechanism – can subsequently cause cell death [15,
16].
1.5.1 Organization and functionality of the NMDA receptor
In contrast to other members of the glutamate receptor family, the NMDA receptor
requires NR-1 as well as NR-2 subunits to form a functional ion channel, whereby
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literature sees this target currently as a heterotetramer, being assembled of combinations of
two NR-1 and two NR-2A through -2D. NR-1 subunits are needed in every functional
receptor, unlike the other subtypes. For example, presence of different NR-2 subunits
varies in specific regional expression patterns [16]. Although many of this information is
mostly based on the analysis of rodents, more and more reports also claim similar, but not
identical expression patterns by the human.
Various studies also dealt with the functionality of the subunits or specific subunit
combinations (Fig. 1.5). Thus, the NR-1 subunit possesses the binding site for glycine (or
D-serine), which must be occupied before binding of glutamate on the NR-2 subunits
which then leads to an opening of the NMDA receptor. Even though, glycine and
glutamate opened under physiological conditions the channel, the passage is still blocked
by an Mg2+ ion at rest. Only after sufficient depolarization, the Mg2+-block is alleviated in
a voltage-dependent manner and lead to a permeation of calcium, sodium and potassium.
This needed depolarization can vary depending on the formation of the receptor; NR-2A or
NR-2B subunits leads to high-conductance channel openings, whereby NR-2C or NR-2D
subunits form receptors with low-conductance channel openings. Another interesting
characteristic of NR-1 subunits is that they can form homo-dimers on their own and it is
also hypothized that such dimers were formed even before the receptor is created. Some of
those studies also show that the constitution of the NMDA receptor is a complex process
requiring time for forming the functional receptor [17].
Fig. 1.5: Model of the NMDA receptor illustrated with
some important binding-sites [16]
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1.5.2 Role of the NMDA receptor on the BBB
A failure of the protective and regulative function of the blood-brain barrier must be seen
as a critical event in the development and progression of several diseases that affect the
CNS. More and more often the NMDA-receptor becomes the center of attention although
the role on the BBB is still not clear. However, the participation of this target in a diversity
of diseases on the blood-brain barrier was reported in several studies. During pathological
conditions like ischemia and stroke the abundant excitatory amino acid glutamate increases
dramatically [18]. This increased level of extracellular glutamate could result in an
overstimulation of several types of glutamate receptors that are expressed on cerebral
endothelial cells [18, 19]. This overstimulation of especially the NMDA receptor causes a
loss in BBB properties and also results in a disruption of the barrier. Increased
permeability of BBB-models due to glutamate overstimulation were already seen before
[18, 20], but the cause of this disruption were not fully understood. However, a clue was
given by András et al. [21], who showed glutamate- induced alterations of tight junction
Fig. 1.6: Signaling Mechanisms that modulate P-gP activity in rodent brain capillaries [23]
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protein expression. Not only an increased BBB permeability and a decreased expression of
tight junctions were results of an overstimulation of the NMDA receptor by glutamate. A
major problem in the therapy of many brain disorders is also the resistance to the drug
treatment [22]. The probably most intensively studied resistance mechanisms are caused by
drug transporters [22, 23, 24]. Studies also already showed that overstimulation of the
NMDA-receptor during diseases like epilepsy is one possible pathway (Fig. 1.6) that lead
to an up-regulation of efflux transporter P-gP [25, 26], what could also prevented by
NMDA-receptor antagonists.
In summary the NMDA-receptor seems to be important at the blood-brain barrier, although
his real functions are still not clear yet. However, a participation of this target during
different pathological disorders was already reported and it remains to be followed if new
therapy approaches could be found targeting NMDA-receptor dependent pathways.
Following tables provide an overview of the substances used in this diploma thesis
including molecular structures and kinetic data related to the NMDA-receptor and other
targets.
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Substance Structual formula EC50-/IC50-values Cells/Cell-line Method and Target Reference
Glycine EC50 = 27 µM Cerebral cortices from Sprague-Dorley
rats
LDH-release assay over
NMDA-receptor
[27]
L-Glutamate acid EC50 = 50 µM Isolated neurohypophysiol nerve terminal
from male Sprague-Dorley rats
Ca2+-influx assay over
NMDA-receptor
[28]
NMDA
N-methyl-D-aspartic acid
EC50 = 364 µM
EC50 = 30 µM
EC50 = 5.7 µM
Cerebral cortices from Sprague-Dorley
rats
Isolated neurohypophysiol nerve terminal
from male Sprague-Dorley rats
Mesencephalic tissue from Wistar rat
foetuses
LDH-release assay over
NMDA-receptor
Ca2+-influx assay over
NMDA-receptor
Ca2+-influx assay over
NMDA-receptor
[27]
[28]
[29]
(+)-MK801
Dizocilpine
(+)-5-methyl-10,11-
dihydro-5H-
dibenzo[a,d]cyclohepten-
5,10-imine maleate
IC50= 120 nM
(Hippocampus)
IC50= 270 nM
(Striatum)
Isolated hippocampus or striatum of 12-
14 days old Wistar rats
Patch-clamp assay of
NMDA-receptor
[30]
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D-APV
2-amino-5-
phosphonopentanoic acid
IC50= 3.7 µM Cerebral cortical neurons Binding-studies assay of
NMDA-receptor
[31]
Memantine
3,5-
diemethyltricyclo[3.3.1.13,
7]decanamin
IC50= 1.4 µM
(Hippocampus)
IC50= 2.93 µM
(Striatum)
IC50= 170 nM
Isolated hippocampus or striatum of 12-
14 days old Wistar rats
Mesencephalic tissue from Wistar rat
foetuses
Patch-clamp assay of
NMDA-receptor
Ca2+-influx assay over
[30]
[29]
Acetylcholine EC50 = 30 µM Xenopus laevis Voltaged-clamped assay
of nAch-receptor
[32]
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(S)-(-)-BayK 8644
(4S)-1,4-dihydro-2,6-
dimethyl-5nitro-4-[2-
(trifluoromethyl)phenyl]-3-
pyridinecarboxylic acid
methyl ester
EC50 = 30 µM
(at –80 mV)
Guineapig ventricular tissue Patch-clamp assay of
voltage-dependent
calcium channel
[33]
Verapamil
(RS)-2-isopropyl-2,8-
bis(3,4-dimethoxyphenyl)-
6-methyl-6azaoctanitril
(+/-)IC50= 1.8 µM
(-) IC50= 900 nM
(+)IC50= 3.6 µM
NCB-20 cells Ca2+-uptake assay of
voltage-sensitive
calcium channels
[34]
Ryanodine
1H-Pyrrole-2-carboxylic
acid,
(3S,4R,4aR,6S,7S,8R,8aS,8b
R,9S,9aS)-dodecahydro-
4,6,7,8a,8b,9a-hexahydroxy-
3,6a,9trimethyl-7-(1-
methylethyl)-6,9-
methanobenzo
[1,2]pentaleno[1,6-bc]furan-
8yl ester
IC50= 10 nM
(skeletal muscles)
IC50= 2.8 µM
(cardiac muscels)
IC50= 2.7 µM NCB-20 cells Ca
2+-uptake assay of
voltage-sensitive
calcium channels
[35]
[34]
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Methyl-ß-cyclodextrine
Removes plasma membrane
Ca2+-ATPase (PMCA) from
the membrane
Ionomycin
Positive control of the
Ca2+-measurement
BAPTA
Negative control of the
Ca2+-measurement
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Fluorescence-dye of the
Ca2+-measurement
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2 Aims of the thesis
The NMDA-receptor is a key player for synapse-formation, -maintenance and is involved
in brain functions like learning, memory or certain behaviours. However, an
overstimulation of this target is also involved in the induction of apoptosis due to
neurotoxic effects. At present time such incidents could increasingly be seen in the light of
pathological conditions like neurodegeneration. Recent studies now also reported the
presence and participation of this glutamate-gated ion-channel in major regulatory
mechanisms at the blood-brain barrier [18, 20, 21, 25]. Therefore, the work of our research
group aids in investigating the hypothesis of an important role of the BBB in
neurodegeneration, to develop possible therapeutic interventions based on this assumption.
Following aims were preassigned or accordingly amended during this diploma thesis:
• The confirmation of the presence of the NR-1 subunit in our human BBB in vitro
model based on the work of Kuhlmann et al. [20] by methods as western blot analysis
and immunofluorescence microscopy. Furthermore, the presence of NR-2A, -2B and –
2C subunits should be checked, in order to get an impression of possible compositions
of a functional NMDA receptor in cell line ECV304.
• The major aim of this thesis was to establish a 96-well plate fluorescence-assay for
measuring the intracellular Ca2+-level for determining the influence of different
NMDA-receptor agonists and antagonists onto it. Thus pathological conditions should
be simulated or prevented, whereby the change in intracellular calcium could be used
as a functional parameter to predict BBB stabilization or disruption.
• Furthermore, methods as the measurement of the transendothelial electrical resistance
(TEER) and western blotting should be performed, in order to investigate the influence
of over-stimulation or inhibition of the NMDA-receptor on specific BBB properties.
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3 Material and Methods
3.1 Chemicals
3.1.1 Antibodies (AB)
Actin (C-11) (A2066), rabbit polyclonal AB, Sigma-Aldrich
Cox-1 (5F6/F4) (sc-52971), mouse monoclonal AB IgG1, Santa Cruz Biotechnology
Cox-2 (5E10/D10) (sc-52972), mouse monoclonal AB IgG1, Santa Cruz Biotechnology
Human E-Selectin/CD62E (BBA16), mouse monoclonal AB IgG1, R&D Systems
ICAM-1 (G-5) (sc-8439), mouse monoclonal AB IgG2a, Santa Cruz Biotechnology
Mdr (C-19) (sc-1517), goat polyclonal AB, Santa Cruz Biotechnology
MRP-1 (IU2H10) (sc-53130), mouse monoclonal AB IgG1, Santa Cruz Biotechnology
NMDAR1 (ab52177), NMDAR-NR-1, rabbit polyclonal AB, AbCam
?????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????
Occludin (33-1500), mouse monoclonal AB, Zymed, Molecular Probes® Invitrogen
ZO-1 (33-9100), mouse monoclonal AB, Zymed, Molecular Probes® Invitrogen
Secondary donkey anti-goat IgG-HRP (sc-2020), Santa Cruz Biotechnology
Secondary goat anti-mouse IgG-HRP (sc-2005), Santa Cruz Biotechnology
Secondary goat anti-rabbit IgG-HRP (sc-2004), Santa Cruz Biotechnology
Secondary goat anti-rabbit IgG-Alexa Fluor 546 (A-11010), Molecular Probes® Invitrogen
Human cerebellum (ab30078), whole cell lysate, adult normal tissue, AbCam
Mouse cerebellum extracts tissue (sacsc-2403), Santa Cruz Biotechnology
3.1.2 Chemicals
1,2-Bis(2-aminophenoxy)ethane-N,N,N´,N´-tetraacetic acid tetrasodium salt (14513),
Sigma-Aldrich
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(+)-MK801 hydrogen maleat (M107), Sigma-Aldrich
(S)-(-)-Bay K 8644 (1546); Tocris Bioscience
Acetylcholine chloride (A2661), Sigma-Aldrich
Acrylamide 2x (10675), Serva Electrophoresis GmbH
Albumin from bovine serum (A8022), Sigma-Aldrich
Ammonium persulfate (13375.01), Serva Electrophoresis GmbH
Amphotericin B (A2942), Sigma-Aldrich
Bicarbonate (25080-060), sterile, 7.5 %, Invitrogen Life technologies
Bromphenol blue (15375), Na-salt, Serva Electrophoresis GmbH
BSA (A-8806), fraction V powder, Sigma-Aldrich
CHAPS (17038), Serva Electrophoresis GmbH
Collagen bovine (150703), MP Biomedicals
Coomassie Brilliant Blue G250 pure (17524), Serva Electrophoresis
D(-)-2-Amino-5-Phosphono-pentanoic acid (A8054), D-APV, Sigma-Aldrich
DMEM (41966), plus 4.5 g/L glucose, L-glutamine and pyruvate, Gibco™
DMSO (1.02952.1000), MerckKGaA
DTT, research grade (20710), Serva Electrophoresis GmbH
Fluo-3-AM (F14218), 1mM solution in DMSO, Invitrogen
Fluorsave™ Reagent (345789), Calbiochem®, Merck Biosciences
Gelatin from bovine skin, Type B (G9391), Sigma-Aldrich
Glycerol (23390), Serva Electrophoresis GmbH
Glycine anal. Grade (23390), Serva Electrophoresis GmbH
Ham´s F12 (21765-029), sterile, Invitrogen Life technologies
HBSS (H4641), 10x, sterile filtered, Sigma-Aldrich
HBSS (H6648), modified, without phenol red, calcium chloride and magnesium sulphate,
Sigma-Aldrich
HBSS (H8264), modified with sodium bicarbonate, without phenol red, Sigma-Aldrich
Heparin sodium salt from porcine intestinal mucosa (5151), Fluka
Hepes (15630-049), 1 M, sterile, Invitrogen Life technologies
IMDM (21980-032), sterile, Invitrogen Life technologies
Ionomycin calcium salt from Streptomyces conglobatus (I0634), Sigma-Aldrich
L-Glutamic acid monosodium salt hydrate (G1626), Sigma-Aldrich
L-glutamine (25030-024), 200mM, sterile, 10x, Invitrogen Life technologies
MeOH (8404), HPLC-grade, Malinchrodt Baker B.V.
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Methyl-ß-cyclodextrin (C4555), Sigma-Aldrich
Milk powder (Art.-Nr.: T145.2) blotting grade, Carl Roth GmbH & Co.KG
Molecular weight standard (161-0373), all blue stained, Precision Plus Protein™, Biorad
Laboratories
N,N´-methylenebisacrylamide 2x (29195), research grade, Serva Electrophoresis GmbH
NCS (26010-74), sterile, Invitrogen Life technologies
N-Methyl-D-aspartic acid (M3262), NMDA, Sigma-Aldrich
PageRuler Prestained Protein Ladder (#SM0671), Fermentas Life Science
Paraformaldehyde (P-6148), Sigma-Aldrich
PBS (14190-094), sterile, Invitrogen Life technologies
Penicillin/Streptomycin (15140-122), 100x, sterile, Invitrogen Life technologies
Pluronic F-127 (P3000MP), 20% solution in DMSO, Invitrogen
Probenecid (P8761), p-(Dipropylsulfamoyl)benzoic acid, Sigma-Aldrich
Propidium iodide (P4170), Sigma-Aldrich
Protease inhibitor cocktail (P8340), Sigma-Aldrich
Ryanodine (1329), Tocris Bioscience
TEMED research grade (35925), Serva Electrophoresis GmbH
Thiourea (88810), Serva Electrophoresis GmbH
Transferrin holo (T-0665), for cell culture, Sigma-Aldrich
TRIS research grade (37190), Serva Electrophoresis GmbH
Triton X-100 pure (37240) Serva Electrophoresis GmbH
Trypsin/EDTA solution (15400-054), sterile, 10x, Invitrogen Life Technologies
Tween 20 (37470), Serva Electrophoresis GmbH
Urea (24524), anal. Grade, Serva Electrophoresis GmbH
Verapamil hydrochloride (94837), Fluka Biochemika
Other chemicals as H2O bidest, H3PO4 (85 % (v/v), HCl (6 N), NaOH (2 N), NaCl, CaCl2,
were made of analytical grade
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3.2 Materials
3.2.1 Materials
96-well cell culture plate (655180), sterile, crystal-clear, F-bottom, Greiner bio-one
96-well microplate (655090), sterile, black with transparent bottom, F-bottom, Greiner bio-
one
12-well plates (353503), BD Biosciences
6-well plates (353046), BD Biosciences
6-well Transwell inserts (353102), BD Biosciences
Autoclave band (84-200-048-CC), steam A, Schinko-Neuroth
Biofuge tubes (Cellstar 188271), 15 mL, Greiner Bio-One GmbH
Biofuge tubes (Cellstar 227261), 50 mL, Greiner Bio-One GmbH
Blottingpads (1703966), extra thick blot paper, 7x 8.4 cm Bio-Rad Laboratories
Cell culture tissue flasks (690160, 658170, 660160) surface area 25 cm², 75 cm², 175 cm²,
Greiner Bio-One GmbH
Cell scraper (541080), sterile, Greiner Bio-One GmbH
Cover slips, diameter 15 mm, Assistant
Eppendorf vials (616201), 1.5 mL, Greiner Bio-One GmbH
Immun-Star WesternC™ (170-5070), Chemiluminescent Kit, Biorad Laboratories
Microscope slides (02 1102), 76 x 26 mm, Menzel-Gläser
Pipette tips (1-111-96-0, 1-201-96-0), 1-200 µL, 1000 µL, Ahn
PVDF membrane, Immuno-Blot™ (162-0177), Biorad Laboratories
Stericups (SCGPU11RE, SCGVU05RE), 1000 mL, 500 mL, Millipore
Sterile filter (P666.1), sterile, 0.22 µm pore size, Carl Roth GmbH
Sterile syringes (300910, 300812, 3001229), 3 mL, 10 mL, 30 mL, BD Biosciences
3.2.2 Devices and softwares
-20 °C freezer, Öko super, Liebherr-International AG
-80 °C freezer, VX 490 F, Jouan, purchased from Ehret Labor & Pharmatechnik
Automatic wet developing machine (Type 5270), Classic E.O.S, Agfa Medical
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Fluorescence microscope Eclipse 50i equipped with an EXFO X-Cite 120 fluorescence
illumination system, Nikon
Gel apparatus: Mini-Protean® 3 with a Power Pack 1000 controller unit, Biorad
Laboratories
LAS 3000™, Fujifilm, Tokyo, Japan
Image Reader Las 3000™ 2.0, Fujifilm, Tokyo, Japan
Incubator Napco 6101-C CO2 (51201015) Ehret Labor & Pharmatechnik
Laminar air flow sterile working bench Biosafe 3, Ehret Labor & Pharmatechnik
Light microscope TMS, Nikon
Microplate reader Polarstar galaxy, BMG Labtechnologies
Microplate reader Tecan Infinite M200i, Tecan
Microplate reader TECAN GeniosPro™, Tecan
Millicell Electrical Resistance System ERS, Millipore
Semi-dry plotter, Trans blot SD semi dry transfer cell, Biorad Laboratories
Shaker GFL, G. Albrechts´s WTW.Nachf.
Thoma chamber superior, Paul Marienfeld GmbH & CoKG
Ultrasound bath Sonorex RK255H, Bandeline
Software Quantity One 4.1.0, Biorad Laboratories
Software Fluostar 4.10, BMG Labtechnologies
Aida – Advanced Image Data Analyser v4.06, Raytest Inc.
Magellan 5.03, Tecan, Mannedorf Switzerland
3.3 Cell lines
3.3.1 Rat glioma cell line C6
Rat cell line C6 was obtained from the German Cancer Research Center Heidelberg
(DKFZ Heidelberg, Germany). C6 cells were grown at passages 20 to 65 in 175 cm²
gelatin coated tissue flasks in C6 medium in order to obtain corresponding astrocyte
conditioned media.
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3.3.2 ECV304
The ECV304 cell line was obtained from the European Collection of Cell Cultures
(ECACC, Wilthshire, United Kingdom). The ECV304 cell line, which was introduced by
Takahashi et al. [36] as a spontaneously transformed human umbilical vein cell line,
exhibits increased TEER when grown in astrocyte conditioned medium (ACM). Moreover,
ECV304 developed many other BBB characteristics including P-glycoprotein (P-gP) or the
expression of tight junctions [6]. ECV304 cells were grown between passages 145 to 190
in 25 cm² or 75 cm² gelatine coated tissue flasks in PBMEC medium.
3.4 Cell culture media and solutions
3.4.1 Trypsin/EDTA solution (200 mL)
10x Trypsin/EDTA solution 20 mL
10x HBSS 20 mL
sterile PBS 154 mL
1 M Hepes 2 mL
7.5 % (v/v) bicarbonate 2 mL
10,000 Units/mL penicillin; 10 mg/mL streptomycin 2 mL
3.4.2 C6 medium (1000 mL)
Ham´s F12 439 mL
IMDM 439 mL
NCS 75 mL
200 mM L-glutamine solution 35 mL
10,000 Units/mL penicillin; 10 mg/mL streptomycin 10 mL
250 µg/mL amphotericin B 1 mL
10mg/mL humane holo-transferrin 500 µL
1000 U/mL heparin 500 µL
27
3.4.3 Astrocyte conditioned medium (ACM) of C6 medium
To obtain astrocyte conditioned medium (ACM) the supernatant of C6 cultures was
collected every other day (25 mL/day). For further uses the collected ACM (500 mL) were
sterile filtered and stored at 4° C.
3.4.4 PBMEC medium (500 mL)
ACM 250 mL
Ham´s F12 103.75 mL
IMDM 103.75 mL
NCS 19 mL
200 mM L-glutamine 17.5 mL
10,000 Units/mL penicillin; 10 mg/mL streptomycin 5 mL
250 µg/mL amphotericin B 500 µL
10 mg/mL holo-transferrin 250 µL
1000 U/mL heparin 250 µL
3.4.5 Gelatine solution 1%
Gelatin from bovine skin, Type B 4 g
Aqua bidest ad 400g
Before use, the gelatine was dissolved for 2 h at >50° C and was then autoclaved.
3.4.6 C6 medium (250 mL), without serum and heparin
IMDM 119,1875 mL
Ham´s F12 119,1875 mL
200 mM L-glutamine 8,75 mL
10,000 Units/mL penicillin; 10 mg/mL streptomycin 2,5 µL
250 µg/mL amphotericin B 250 µL
10 mg/mL holo-transferrin 125 µL
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3.5 Cell culture work/protocol
3.5.1 Coating of cell culture flasks or 96-well plate
Before cell culture flasks are used, they were coated with a 1 % sterile gelatin solution for
20-30 min at RT under the laminar.
T25 flasks à 2 mL 1% gelatin solution
T 75 flasks à 6 mL 1% gelatin solution
T175 flasks à 10 mL 1% gelatin solution
96-well plate à 50 µL/well 1% gelatin solution
It should be noted that the whole surface was covered with the gelatin solution. After the
incubation period the remaining supernatant was removed and the plate/flask was ready for
use.
3.5.2 Subculturing of ECV304 or C6 cells
The consumed medium was removed from a confluent cell layer and was washed with
sterile PBS twice. Further on, Trypsin/EDTA solution was put into the flask and the
confluent cells were incubated for about 3-5 min (ECV304) at room temperature (RT).
During this the cell-shape changed from a cobble-stone morphology to a nearly spherical
morphology which was controlled microscopically. For C6 cells the Trypsin/EDTA
solution was only for about 10 sec on the surface because C6-cells detach very fast. When
ECV304 cells nearly reached this spherical state, Trypsin/EDTA solution was removed.
Then the flask was knocked for a few times on a table to detach the spherical cells from the
surface. Afterwards growth medium was added again into the flask over the whole surface
on nine specific points to detach the remaining cells. To get a homogeneous cell
suspension the solution with the detached cells was pulled up and down for about 20 times.
For further subculturing an appropriate volume of this suspension was put in a new gelatin-
coated flask and was filled with growth medium to the adequate volume of the flask. For
further cultivation the flask was shaken a little to distribute the cells on the whole surface
before it is placed again into the incubator at 37° C, 5 % CO2 and 96 % humidity.
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T25 flask à 2 mL PBS or Trypsine/EDTA solution
T75 flask à 6 mL PBS or Trypsine/EDTA solution
T175 flask à 10 mL PBS or Trypsine/EDTA solution
ECV304 or C6 cells were normally subcultured in a ratio of 1:10 or 1:20.
T25 flask à 5 mL growth medium
T75 flask à 15 mL growth medium
T175 flask à 25 mL growth medium
3.5.3 ECV304 culture in a Transwell™ model and measurement of the
transendothelial electrical resistance (TEER)
Before ECV304 cells were seeded, transwell inserts had to be coated with collagen.
Therefore 150 µL of a 0.14 mg/mL collagen solution were distributed on a transwell-
surface of 4.2 cm². It should be taken care that the whole surface of the insert is covered in
the collagen solution. Then the 6-well plates with the inserts were put for one hour into the
incubator (at 37° C, 5 % CO2 and 96 % humidity). Afterwards the remaining supernatant
of the collagen solution was removed and the inserts were ready for seeding the ECV304
cells.
ECV304 cells were seeded at a density of 80 000 cells/cm² on the Transwell filter inserts.
Cells were counted by using a thoma chamber after they had been detached from the
surface of T25 or T75 flasks with Trypsin/EDTA solution and resuspended in an adequate
amount of growth medium. It is now beneficial for getting a uniform attachment on the
inserts, to prefill each well with 3 mL, the inserts were filled with a certain amount of
medium according to the counted cell number that was subtracted from a total volume of 2
mL. Then the cell suspension was added to the inserts and shaken afterwards to get a
uniform distribution and subsequent attachment on the surface of the insert. ECV304 cells
were cultured for 14 days in an incubator at 37° C, 5 % CO2 and 96 % humidity, whereby
the medim was changed every other day.
After the cells were cultured for 7 days, the transendothelial electrical resistance (TEER)
was measured with a Millipore Millicell Electrical Resistance System. Based on Ohm´s
law –    V= I x R (V = voltage, I = current, R = resistance) – the resistance reflects the
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tightness of the cell–surface against small ions. Following protocol was used for the
measurements:
(a) During the days when the measurement electrode was not used, it was stored in 70 %
(v/v) ethanol
(b) 6-well plates were removed from the incubator and put under the laminar air flow
(LAF). Afterwards the old medium was changed immediately and replaced with new,
pre-warmed medium. Since the electrical resistance is temperature dependent, the
measurements were carried out after incubation at RT for 1 hour.
(c) Electrodes were plugged in a 15 mL Biofuge tube with an adequate amount of growth
medium to equilibrate them at RT for at least 30 minutes.
(d) Before measurement, plug the electrode for about 10 seconds in 70 % (v/v) ethanol, tap
hanging drops off and dip it then into the growth medium.
(e) Afterwards the electrodes were placed into the first well. Insert was oriented probably
in the middle of the well, so that no liquid film was formed due to capillary forces
between the walls of the insert and the well. Half of the distance between the boarder
of the well and the boarder of the insert the electrode was situated, so that one part
extended into the well reaching the ground and one into the insert not touching the
insert membrane.
(f) The electrode should be oriented as vertical as possible and only touched on the blue
top by the fingers. When the correct vertical position was found, the measurement-
button was pressed and the value of the display was read.
(g) Blank inserts had been coated at the same time as the inserts, on which the cells were
cultured, and were measured in the same series.
(h) After every measurement the electrodes were put into 70 % (v/v) ethanol for 10
seconds and dipped afterwards in growth medium again.
(i) After finishing the measurements, the electrodes were put in 70 % (v/v) ethanol for
storage again.
To calculate the TEER following formula was used:
TEER [Ohm * cm²] = (TEERcell – average TEERblank) * surface area
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3.5.4 Influence of glutamate on the TEER
Cells were cultured in 6-well plates with inserts and TEER was measured as it is described
in 3.5.3. After the cells were cultured for 14 days the experiment was performed under
following parameters:
(a) Electrode was stored in 70 % (v/v) EtOH when it was not used.
(b) 6-well plates were removed from the incubator and put under the LAF. Without a
medium change before, the plates were incubated for 1 hour at RT for temperature
adjustment.
(c) – (h) are similar to working streams as in 3.5.3 (c-h) to measure the TEER.
(i) After this measurement series, the electrode was plugged into 70 % (v/v) ethanol for 10
seconds and stored afterwards in serum– and heparin– free C6-medium for
equilibration.
(j) Now the 6-well plates and inserts were washed twice with sterile PBS.
(k) Afterwards serum– and heparin– free C6-medium was added into the wells and inserts
(3 mL per well, 2 mL per insert). After another 30 min. incubation at RT TEER was
measured again. In those wells where an antagonist / channel blocker was added, this
incubation time for RT adjustment was also used as pre-incubation step with the
channel blockers. Therefore, serum– and heparin– free C6-medium was supplemented
with the antagonist at the appropriate concentration.
(l) Serum– and heparin– free medium or pre-incubation (in the case of glutamate +
MK801) medium were replaced with the experimental medium at RT in the wells and
the inserts.
(m)Now the wells were incubated at RT under the LAF and TEER was measured every
hour for at least 3 hours.
(n) Afterwards wells and inserts were washed with sterile PBS twice and were refilled with
serum- and heparin- free C6-medium and incubated in an incubator at 37° C, 5 % CO2
and 96 % humidity for further 21 hours.
(o) On the next day, one hour before a total experimental time of 24 hours was reached, the
6-well plates were taken out of the incubator and put under the LAF to adjust at RT
again.
(p) Electrodes were plugged into a Biofuge tube with serum– and heparin– free medium to
equilibrate it.
(q) TEER was measured again after 24 hours.
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(r) Afterwards the medium was aspirated and the cell layers onto the inserts were then
washed twice and prepared for cell-lysis prior subsequent western blot analysis.
3.5.5 Protein analysis
Cell lysis stock buffer was stored at –20° C in corresponding aliquots and only thawed
shortly before use. 400 µL stock lysis buffer were mixed with 2 mg DTT and 4 µL
protease inhibitor cocktail. 6-well plates with inserts were placed on ice, growth– or
experimental– medium was exhausted and washed twice with PBS. 50 µL of the modified
cell lysis buffer were distributed on the cell surface of each insert. Cell disruption was
monitored by light microscopy and cells were gently threadbared with the aid of a scraper.
25 µL of this lysis solution containing the cell fragments were immediately stored at –80°
C, the remaining solution was centrifuged at 12,000  rpm for 10 minutes. Now the
supernatant was also stored at -80° C until further protein analysis.
Cell lysis stock buffer: 8 M Urea
2 M Thiourea
0.5 % Trition X-100
2 % Chaps
5 mM EDTA
3.5.5.1 Bradford protein determination
In order to determine the protein concentration in a solution – needed for the appropriate
volume of a protein solution for western blot analysis – Bradford protein assays were
carried out using following protocol:
(a) Protein samples and a BSA standard (1 mg/mL) were thawed on ice.
(b) On each measurement day a new calibration curve had to be made. Therefore, BSA
standard (1 mg/mL) was diluted to concentrations of 0.1, 0.05 and 0.025 mg/mL.
(c) 100 µL of each BSA dilutions were added to 1 mL of a pre-warmed (RT) Bradford
solution and mixed gently into Eppendorf vials.
(d) After an incubation at RT for five minutes, the solution was put into a semi-
microcuvette and absorption was measured at 595 nm against a blank consisting of 1
mL Bradford solution and 100 µL H2O bidest. (instead of 100 µL protein solution).
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(e) Afterwards protein samples were measured the same way. Samples had to be diluted
with H2O bidest. in order to receive absorption values within the linear absorption
range from 0.2-0.7. BSA dilutions were measured in triplicates and protein samples
were measured in duplicates (when values were related).
(f) Through the equation obtained by linear regression analysis of the calibration curve,
concentrations of protein samples could be calculated.
Bradford solution (100 mL):
Coomassie Brilliant Blue G250 10 mg
96 % (v/v) Ethanol 5 mL
85 % (v/v) H3PO4 10 mL
H2O bidest. 85 mL
Coomassie brilliant blue G250 was weighted and mixed with circa 40 – 60 mL H2O
bidest. Then, 10 mL of 85 % (v/v) H3PO4 was added followed by 5 mL of 96 %
(v/v) EtOH. Afterwards it was filled to a total volume of 100 mL with H2O bidest. and 
stirred afterwards for 30 – 60 minutes. Finally, the solution was filtered and stored
at 4° C.
3.5.5.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Two different SDS-PAGE separation gels consisting of either 12.5 % acrylamide solution
(NMDAR-subunits, Cox-1, Cox-2, E-selectin, ICAM, Occludin, ZO-1) or 7.5 %
acrylamide solution (Mdr, MRP-1) were used. Electrophoretic separation  were undertaken
in a Mini-Protean® 3 apparatus at 125 V controlled by a Power Pack 1000 unit for 75
minutes and was based on following protocol (volume-composition of gels is referred for
making two gels):
(a) Prepare separation buffer, acrylamide buffer and APS before any gel is casted.
Separation buffer 4x (500 mL):
Tris (1.5 M) 90.8 g
SDS (0.4 % (w/v)) 2 g
H2O bidest. ad 500 mL
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pH = 8.8 with 6 N HCl, storage at RT
Acrylamide (400 mL):
Acrylamide (30 % (w/v)) 120 g
N,N´-methylenebisacrylamide (0.8 % (w/v)) 3.2 g
H2O bidest. ad 400 mL
Storage at 4° C
APS (50 mL):
Ammonium persulfate 5 g
H2O bidest. ad 50 mL
Storage in 1 mL aliquots at –20° C
Separating gel 12.5 % (v/v) (16 mL):
H2O bidest. 5.42 mL
Separation buffer 4x 4 mL
Acrylamide solution 6.49 mL
TEMED 10 µL
APS 75 µL
Separating gel 7.5 % (v/v) (16 mL):
H2O bidest. 8.1 mL
Separation buffer 4x 4 mL
Acrylamide solution 3.9 mL
TEMED 10 µL
APS 75 µL
(b) It should be noted that the solution should be degassed by ultrasonication before
TEMED and APS were added. An appropriate volume of the complete solution was
quickly filled into the Mini-Protean® 3 apparatur and covered afterwards with app. 0.5
cm H2O saturated n-butanol to ensure a straight upper egde of the separation gel. After
the separation gel has polymerized the n-butanol was removed. Now the edge was
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washed twice with H2O bidest.. Afterwards it was dried with a small sheet of a filter
made of paper.
(c) The stacking gel was then prepared, as it is described following.
Stacking gel buffer 4x (100 mL):
Tris (0.5 M) 6.06 g
SDS (0.4 % (w/v)) 0.4 g
H2O bidest. ad 100 mL
Storage at RT
Stacking gel (5 mL):
H2O bidest. 3.05 mL
Stacking gel buffer 4x 1.25 mL
Acrylamide solution 0.65 mL
TEMED 5 µL
APS 50 µL
Similar to the preparation of the separation gel, the solution could be degassed before
TEMED and APS were added. Now the remaining space in the Mini-protean® 3
chamber was filled with the stacking gel and the combs were placed quickly before the
gel was polymerized (it should be tried to prevent any air bubbles when adding the
combs).
(d) Laemmli buffer was thawed and mixed with 6.2 mg DTT/mL. Then, a determined
volume of the samples (determined through Bradford-Protein assay) were mixed with
the Laemmli/DTT buffer to reach a total volume of 20 µL and 20 µg total amount of
protein.
Laemmli buffer (50 mL):
Tris (250 mM), pH = 6.8 1.514 g
SDS (8 %) 4 g
Glycerol (20 %) 10 mL
Bromphenol blue (1 % stock solution) 1 mL
H2O ad 50 mL
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The needed amount of Tris was weighted in, dissolved it in circa 20 mL H2O and
adjusted to a pH = 6.8 (circa 3 mL of a 6 N HCl) and was then filled with missing H2O.
Carefully 4 g of SDS was added, followed by adding glycerol and bromphenol blue (1
% stock solution while stirring constantly until everything is dissolved).
1 mL aliquots are stored at –20° C
before use 6.2 mg DTT/mL was added
(e) Now the mixture consisting of protein sample and Laemmli/DTT was heated up to 95°
C for 10 minutes and put directly afterwards on ice.
(f) Cathode and anode buffer (1x) were prepared from the stock solutions, while the
samples were heated.
Cathode buffer 10x (1000 mL):
Tris (250 mM) 30.2 g
SDS (1 % (w/v) 10 g
Glycine (1.92 M) 144.2 g
H2O bidest. ad 1000 mL
Storage at RT, 1:10 dilution shortly before use
Anode buffer 10x (1000 mL):
Tris (250 mM) 30.2 g
SDS (1 % (w/v) 10 g
H2O bidest. ad 1000 mL
Storage at RT, 1:10 dilution shortly before use
(g) The combs were carefully removed from the polymerized stacking gel and the pockets
were filled with cathode buffer. Afterwards the chilled samples and an internal
standard (either 2-4 µL of PageRuler Prestained Protein Ladder or Molecular weight
Precision Plus Protein™ were used) as a reference were added into the pockets.
(h) Mini-Protean®  – system was build together, adequate volume of anode buffer (300
mL) was added to the exterior chamber and cathode buffer was filled in the interior
chamber. Now the system was started at 125 V controlled by a Power Pack 1000 unit
for 75 minutes.
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3.5.5.3 Western blotting
Following protocol was used, after samples were separated by electrophoresis (described in
3.5.5.2):
(a) PVDF membrane was given into a dish with methanol and soaked there for a few
seconds. Afterwards the membrane and blotting pads were stored in a dish with
Towbin blotting buffer for 15 – 30 minutes.
Towbin blotting buffer (1000 mL):
Tris (25 mM) 3.3 g
Glycine (192 mM) 14.4 g
Methanol (20 % (v/v)) 200 mL
H2O bidest. ad 1000 mL
Storage at 4° C, reuseable for about 10 times
(b) After the electrophoretic separation was finished (~ 75 minutes). The stacking gel was
carefully removed with a knife and discarded afterwards.
(c) Two wet blotting pads were put into a semi-dry blotter, followed by the wet PVDF
blotting membrane and afterwards carefully the gel was put upon it. Another two wet
blotting pads were put at top of this to complete the sandwich-assembly. Possible air
bubbles were removed and little blotting buffer was distributed on the surface. Now the
semi-dry blotter was closed, for each gel 50 mA were set up (100 mA for two gels) and
the blotting process was started for one hour.
(d) Afterwards the semi-dry blotter was opened and as a control the migration of the
standard into the PVDF membrane was checked. If nearly everything migrated, the
PVDF membrane was washed for two times with H2O bidest. and soaked into a dish
with milk powder solution over night (shaking at 10 % at 4° C).
Milk powder solution (100 mL):
Milk powder (5% (w/v)) 5 g
TBS 10x 10 mL
Tween 20 0.1 mL
H2O bidest. ad 100 mL
Freshly prepared
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TBS 10x (1000 mL):
Tris 30.12 g
NaCl 84 g
H2O bidest. ad 1000 mL
pH = 7.8 with HCl, storage at RT
(e) On the next day the PVDF membrane was washed with 0.1 % TBS-T solution for three
times. Each washing step was performed for 10 minutes and shaked at 10 %.
TBS-T 0.1% (1000 mL):
TBS 10x 100 mL
Tween 20 (0.1 % (v/v) 1 mL
H2O bidest. ad 1000 mL
Storage at RT
(f) Now the solutions for the primary antibody should be prepared. Primary antibody for
Cox-1, Cox-2, ICAM-1, MRP-1, NMDAR-subunits, Occludin and ZO-1 was diluted
1:200, for Mdr and E-selectin 1:100, and for Actin 1:1666.7 in 10 mL (for 2
membranes) milk powder solution.
(g) If it’s necessary, the membrane was cut in appropriate parts, so that each part can be
incubated with the different antibodies. Therefore 5 mL of each primary antibody
solution was added to the appropriate part of the PVDF membrane and incubated for
one hour (shaking at 10 %).
(h) Afterwards the primary antibody solution was removed and the membrane was washed
three times with 0.1 % TBS-T solution for 10 minutes (shaking at 10 %).
(i) During the washing process the secondary antibody could be prepared. Secondary
antibodies for anti-mouse, anti-goat and anti-rabbit were diluted 1:5000, and the
secondary anti-rabbit antibody for Actin 1:10000 in 10 mL (for two membranes ) milk
powder solution. 5 mL secondary antibody solution was added to each membrane and
every membrane part was incubated at 10 % shaking for 1 hour.
(j) After the incubation with the secondary antibody, the membrane parts that were
separated just a few steps earlier were fitted together again and were then treated with
the Immun-Star WesternC™ chemiluminescent kit. Referred to two membranes, 1.5
mL of solution A were mixed with 1.5 mL of solution B and afterwards 1.5 mL were
applied to each membrane to visualise where the secondary antibody had bound. Shake
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gently for about 5 minutes, to ensure that the whole surface of the membrane was
covered in the chemiluminogen solution.
(k) Compartible membrane parts were covered in a transparent foil, air bubbles were
removed and everything were developed in either a BioRad imager or the image reader
Las 3000™.
3.5.6 Immunofluorescence microscopy
Cover slips with a diameter of 15 mm were put under the LAF by means of a tweezer into
each well of a 12-well plate. Following 2 mL of sterile filtered 70 % (v/v) ethanol was
added into each well for desinfection for at least 30 – 60 minutes. Ethanol was removed
afterwards and cover slips were then washed with 2 mL (per well) sterile PBS 2-3 times.
Please note that residual ethanol should be removed with a pipette. Optionally, the 12-well
plate could now be put with its lid into a drier to ensure everything of the ethanol was
evaporated (please note that the top cover shouldn´t  be removed during this step,
otherwise the plate would be contaminated). Afterwards the 12-well plate was put again
under the LAF and ECV304 cells could be seeded at a densitiy of 80,000 cells/cm² (please
note that no coating was necessary for the attachment and growth of ECV304 cells). Cells
were grown for 7 or 10 days prior to immunofluorescence staining, medium was changed
every other day. Following two protocols were used for staining and preparation for
immunofluorescence microscopy.
3.5.6.1 Protocol using methanol (MeOH)
(a) MeOH was put into a 50 mL Biofuge tube and precooled at –20° C for at least 30 – 60
minutes.
(b) 12-well plates with cultured ECV304 cells on the cover slips were washed for three
times with 2 mL/well PBS. After the last washing step all residues of PBS should be
removed as good as possible with a pipette. Following 2 mL of the precooled (–20° C)
MeOH were given into each well for cell fixation and then stored at –20° C for 20
minutes.
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(c) After incubation at –20° C MeOH was removed and washed for 2 times with 2 mL
PBS, afterwards it was refilled with 2 mL PBS and incubated at RT for 20 minutes for
rehydratisation.
(d) The PBS was removed and residuals were aspirated with a pipette. Now the cell layer
was incubated with 400 µL of the primary antibody solution (1:100 in 1 % BSA/PBS)
at 37° C for 1 hour.
(e) The primary antibody solution was then removed and washed for three times with 2
mL/wll PBS (please note that after each washing step possible solution leftovers are
removed with a pipette).
(f) Then 400 µL of the secondary antibody solution (1:100, either FITC or IgG-Alexa
Fluor 546 was used, in 1 % BSA/PBS including 1 µg/mL propidium iodide) was
incubated at 37° C for 30 minutes.
(g) After the incubation, the cell layer was washed again with 2 mL PBS per well for three
times.
(h) Slides were cleaned with 70 % (v/v) EtOH before the cover slips were mounted.
(i) One cover slip after another were removed from the wells, remaining PBS was
carefully absorbed by a paper towel and mounted afterwards using a drop of FluorSave
on a slide.
(j) Then the slides with the mounted cover slips were dried over night in the dark at RT
(k) Before slides are used for immunofluorescence microscopy they were gently cleaned
with 70 % (v/v) EtOH to remove salt crystals onto the glass surface.
3.5.6.2 Protocol using paraformaldehyde and 0.1 % Triton-X 100
(a) A 2 % paraformaldehyde (P-FA) solution (protocol see below) and a 50 mM NH4Cl-
solution in PBS were prepared.
(b) 12-well plates with cultured ECV304 cells on cover slips were washed for two times
with 2 mL/well PBS, whereas after the last washing step all leftovers of PBS should be
removed completely with a pipette.
(c) 750 µL – 1000 µL of the 2 % P-FA solution in PBS were added into each well for cell
fixation and incubated for 10 – 15 minutes at RT.
(d) The P-FA solution was efficiently removed and washed afterwards two times with 2
mL/well PBS (leftovers of the solution should be removed with a pipette).
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(e) Afterwards 750 µL – 1000 µL of a 50 mM NH4Cl solution in PBS were added to each
well and incubated for 10 – 15 minutes
(f) The solution was removed and washed again twice with PBS
(g) Optional: If cells should be permeabilized, add 750 µL – 1000 µL of a 0.1 % Triton-X
100 solution in PBS to each well and incubate for 7 minutes. Afterwards wash again
twice with 2 mL/well PBS and remove leftovers with a pipette. Meanwhile this
permeabilisation step, slips with cells which should not be permeabilized can be left in
PBS.
(h) Now the cell layer was incubated with 400 µL of the primary antibody solution (1:100
in 1 % BSA/PBS) at 37° C for 1 hour.
(i) The primary antibody solution was removed and washed for three times with 2
mL/well PBS (please note that after each washing step possible solution leftovers were
removed with a pipette).
(j) Then 400 µL of the secondary antibody solution (1:100, either FITC or IgG-Alexa
Fluor 546 was used, in 1 % BSA/PBS including 1 µg/mL propidium iodide) were
added to each well and incubated at 37° C for 30 minutes.
(k) Again each well was washed for three times with 2mL PBS
(l) Then the slides had been cleaned with 70 % (v/v) EtOH before slips were mounted.
(m)One cover slip after another were removed from the wells, remaining PBS was
carefully absorbed by a paper towel and mounted afterwards using a drop of FluorSave
on a slide.
(n) Then the slides with the mounted cover slips were dried over night in the dark at RT
(o) Before slides are used for immunofluorescence microscopy they were gently cleaned
with 70 % (v/v) EtOH to remove salt crystals onto the glass surface.
Preparing a 2 % P-FA solution in PBS:
Paraformaldehyde 600 mg
1 mM NaOH 3 drops
10x PBS 3 mL
Aqua bidest. ~27 mL
600 mg of P-FA were laced with ~20 mL H2O in an appropriate Erlenmeyer flask and
then 3 drops of a 1 mM NaOH solution were added to this. A small magnetic stir bar
was given into the Erlenmeyer flask, the opening was sealed with parafilm and placed
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afterwards on a magnetic stirrer with an adjusted temperature of 60° – 70° C. It was
waited until everything was dissolved – this will take for about 1 hour – and then
cooled down to RT again. 3 mL of a 10x PBS were added into the Erlenmeyer flask
and refilled afterwards with H2O to a total volume of 30 mL.
3.5.7 Intracellular Ca2+ - level assay
As a consequence of the activation of NMDAR, a calcium influx into the cell takes place.
Therefore one of our aims was to measure the change of the intracellular calcium level as a
functional parameter of the NMDA receptor activation by a fluorescence method in a 96-
well plate format. A steady-state as well as a kinetic-like protocol had been developed to
determine changes in the intracellular Ca2+-level. Both finally developed protocols were
described in the following paragraphs. Differences in the experiments in comparison to
these protocols were described later in the appropriate result part.
3.5.7.1 Culturing ECV304 cells in a 96-well plate
Cells were seeded on a black, gelatine coated 96-well plate at a density of 50,000
cells/cm². Mostly the ECV304 cells were cultured for 7 days (experiments where cells had
been cultured for 4 or 14 days were also performed), whereby medium was changed every
other day.
A membrane-permeable form of the fluorescence dye Fluo-3 called Fluo-3-AM was
chosen, thus cells could be loaded via incubation. However, due to a relatively low water
solubility of the AM ester Pluronic F-127 was also added as a dispersing agent to facilitate
the loading. Inside the cells Fluo-3-AM was hydrolyzed to the active Ca2+-binding form by
endogenous esterases. In order to minimise efflux of the cleaved Fluo-3 out of the cells,
mediated by MRP or OAT transporters, the inhibitor Probenecid (2.5 mM) was added.
Three different multiplate readers were tested in order to investigate the differences
between each system and to find the optimum one. The instrument and appropriate settings
were given below.
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3.5.7.2 Steady-state protocol
(a) Appropriate amounts of Probenecid were weighted in and solutions were made by
dissolving the Probenecid in HBSS/20 mM Hepes to reach a solution of 2.5 mM. Either
HBSS with Mg2+ and Ca2+ were used (H8264), or HBSS (H6648) without Mg2+ and
Ca2+, in which Ca2+ was added afterwards.
To dissolve Probenecid completely in HBSS, everything was given into a ultrasonic
bath for at least 1 hour (shaking or vortexing sometimes during this process would be
helpful).
F1: Probenecid 18.8 mg
HBSS with Mg2+ and Ca2+ (H8264) 25.8111 mL
1 M Hepes (20 mM) 526.7 µL
F2: Probenecid 18.8 mg
HBSS without Mg2+ and Ca2+ (H6648) 25.8111 mL
1 M Hepes (20 mM) 526.7 µL
à Then 7.6 mg CaCl2 were weighted in and dissolved in 25.84 mL of the prepared
F2 solution.
This step could also be performed one day before the experiment and solutions were
stored at 4° C overnight, since the dissolving process lasts quite long.
(b) 1 % Albumin from bovine serum (A8022) was added to the Probenecid/Hepes/HBSS
solutions. Solutions were then gently mixed by a vortex to avoid too much foam
formation.
(c) pH value was adjusted with 2 N NaOH to pH = 7.4
(d) A 100µL aliquote of Pluronic F-127 was incubated at 37° – 40° C for at least 1 hour.
(e) Fluorescence loading solution was prepared. Therefore 76 µL of Fluo3-AM was mixed
with 76 µL of Pluronic F-127 and vortexed afterwards. Then 18.848 mL of F1-solution
(with Mg2+ and Ca2+) was added and stored at RT in the dark until its use.
(f) 96-well plate with cells were taken out of the incubator and washed three times with
200 µL HBSS (H8264) per well using a multichannel pipette.
(g) 200 µL of the F1-solution were given into each well of row 1 from the 96-well plate as
a blank value. All other wells (rows 2 – 12) were filled with 200 µL of the fluorescence
loading solution prepared in (e). Then the whole plate was incubated at RT in the dark
for one hour.
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(h) Unless the experimental mediums were not prepared until now, this should be finished
during the incubation time. It should be noted that all solutions had to be prepared as
4x concentrated in F2-solutions, since the solutions will be diluted 1:4 in the addition
step (m). Then ~60 µL of experimental mediums were pre-pipetted into defined wells
of an transparent 96-well plate, so that these solutions could then easily taken out with
the multichannel pipette. The 96-well plate was then incubated at 37° C.
(i) After the loading the black 96-well plate with cells was washed again for two times
with HBSS (8264) and refilled with 75 µL per well of the F2-solution. Then, the 96-
well plate was incubated at 37° C in the dark for 30 minutes (preferably in a CO2-
incubatior).
(j) The plate reader should be turned on now, if it’s not done until yet and heated to 37° C.
Also the used measurement-protocol could be loaded.
Microplate reader Tecan Infinite M200i:
Measurement Mode: Fluorescence Bottom Reading
Excitation Wavelength: 485 nm
Excitation Bandwidth: 9 nm
Emission Wavelength: 535 nm
Emission Bandwidth: 20 nm
Interval Time: Minimal
Gain: 180 – 190
Number of Reads: 25
Integration Time: 25
Lag Time: 0 µs
Microplate reader TECAN GeniosPro™:
Mode: Fluorescence Bottom Reading
Excitation Wavelength: 485 nm
Excitation Bandwidth: 20 nm
Emission Wavelength: 535 nm
Emission Bandwidth: 25 nm
Gain: 62 nm
Number of Reads: 20
Integration Time: 20
Lag Time: 0 µs
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Time between move and flash: 40 ms
Microplate reader Polarstar galaxy:
Excitation filter: 485 nm – P
Emission filter: 520 nm – 535 nm
Gain: 128
Number of flashes: 20
Reading direction: horizontal
(k) After the incubation the 96-well plate with the cells were given into the analyzer and
the base-fluorescence was measured. Therefore 2x 4 Cycles were measured in order to
get a good baseline for the starting-point (~10 minutes).
(l) Now 25 µL of the experimental medium of the prepared 96-well plate from step (i)
were quickly pipetted in reverse mode into the defined wells (this step accords to a 1:4
dilution, therefore the experimental medium was 4x concentrated with the applied
substances in step (i).
(m)The measurement was carried out for 25-35 cycles.
(n) Now a solution of HBSS/1 % Triton X-100 was prepared for subsequent cell lysis.
(o) After the experiment was finished the experimental medium was removed from the
cells and replaced with 100 µL HBSS/1 % Triton X-100 to check the loading capacity.
(p) The measuring was started 5 minutes after adding the solution from step (p) by using 4
cycles.
3.5.7.3 Kinetic-like protocol
(a) Appropriate amounts of Probenecid were weighted in and solutions were made by
dissolving the Probenecid in HBSS with Mg2+ and Ca²+ (H8264) to get a 2.5 mM
solution. To dissolve Probenecid completely in the HBSS, everything was given into a
ultrasonic bath for at least 1 hour (shaking or vortexing sometimes during this process
would be helpful).
F1: Probenecid 32.5 mg
HBSS (8264) 45.55 mL
This step could also be performed one day before the experiment and solutions were
stored at 4° C overnight, since the dissolving process lasts quite long.
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(b) Add 1 % Albumin from bovine serum (A8022) to the Probenecid/Hepes/HBSS
solutions and mix it gently on a vortex to avoid too much foam formation.
(c) pH was adjusted then with 2 N NaOH to pH = 7.4
(d) A 100µL aliquote of Pluronic F-127 was incubated at 37° – 40° C for 1 hour.
(e) Fluorescence loading solution was prepared. Therefore 42 µL of Fluo3-AM was mixed
with 42 µL of Pluronic F-127 and vortexed afterwards. Then 10.416 mL of F1-solution
(with Mg2+) was added and stored at RT in the dark until its used.
(f) Prepare all solutions needed for the experimental medium and pre-pipette them into a
96-well plate.
(g) 96-well plate was taken out of the incubator. First, row 1 – 4 were washed three times
with 200 µL HBSS per well, followed by adding 200 µL F1-solution to row 1 and 2,
then 200µL of the fluorescence loading solution were added into the wells of row 3 and
4.  The addition of fluorescence solution equals to the starting point of the loading
period.
Seven minutes after Fluo3-AM solution was given to row 3 and 4, row 5 and 6 were
washed three times with HBSS (this will take for about 3 minutes). After the washing
step 200 µL Fluo3-AM was given to row 5 and 6.
Repeat this step again for row 7 and 8, during the time when nothing is done with the
96-well plate; store it at RT in the dark.
(h) Turn the analyzer on an set the parameters
Microplate reader Tecan Infinite M200i:
Measurement Mode: Fluorescence Bottom Reading
Excitation Wavelength: 485 nm
Excitation Bandwidth: 9 nm
Emission Wavelength: 535 nm
Emission Bandwidth: 20 nm
Intervaltime: Minimal
Gain: 180 – 190
Number of Reads: 25
Integration Time: 25
Lag Time: 0 µs
(i) One hour after row 3 and 4 were loaded with the fluorescence dye, wells of row 1-4
were washed with HBSS twice, followed by adding 75 µL of F1-solution to row 1-4
and incubating at RT in the dark for 30 minutes.
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One hour after row 5 and 6 were loaded the wells were equally treated as row 1-4.
Same steps were repeated with row 7 and 8.
(j) A few minutes after 75 µL were added to row 7 and 8, measuring of the baseline from
row 1 and 2 was started by measuring 2x 4 cycles. 25 µL of the control medium were
given into row 1 and 2 (this was performed while the 96-well plate still stands close to
the analyzer) and as fast as possible the change in fluorescence was measured during
20 cycles.
(k) After 30 minutes incubation of row 3 and 4 the fluorescence-baseline was determined
by measuring 4 cycles. Then 25 µL of an experimental medium was given into each
well of row 3 and 4, followed by measuring the change in the fluorescence level by 20
cycles (whole step (l) takes about 8-9 minutes).
(l) Now this steps were repeated with row 5/6 and 7/8 as well, since a time interval of 10
minutes was set between the incubation of the paired rows 3/4, 5/6 and 7/8.
(m)After measurements of rows 7/8 were finished, the measuring of the whole plate from
row 1-8 with 20 cycles was carried out.
(n) After the experiment was finished the experimental medium was removed from the
cells and replaced by 100 µL HBSS/1 % Triton X-100 to check the loading capacity.
(o) 5 minutes after the solution from step (n) was added the measuring started by using 4
cycles.
3.5.7.4 Variable parameters in the calcium influx protocol
• Instead of Albumin also NBS was used in some experiments.
• It was checked if Probenecid is needed for the experiment to prevent Fluo-3
bleeding out from the cells.
• The fluorescence dye Ca-green-AM was also tested.
• Experiments were performed at RT and at 37° C analyzer temperature.
• Cells were loaded with the fluorescence dye Fluo3-AM for 30 minutes instead
of normally 1 hour.
• Experiments were performed where cells were cultured for 4 or 14 days, instead
of normally 7 days.
• The buffer Hepes wasn´t used in every experiment.
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• At the beginning of the experiments, one complete row was filled with one
substance (n=8), this means:
Row 1 = cells without fluorescence dye
Row 2 = control
Row 3 = positive control (= Ionomycin)
By-and-by this was changed to follwoing distribution on the 96-well plate (only
steady state experiments). The blank, where cells were not loaded with any
fluorescence dye, was always distributed in row 1; all the other substances and
controls were distributed in a pre-defined sequence between rows 2 – 12. Starting
with the first substance/control in the first well of row 2, followed by the next
substance added to the second well of row 2 and so on. So a variable and random
distribution could be achieved by this way, what probably resulted in more accurate
results.
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4 Results
4.1 Presence of the NMDA receptor in cell line ECV304
Kuhlmann et al. [20] already showed the presence of the glycine binding NR1 subunit on
ECV304 cells and also assumed this target to be functional. We wanted to check in more
detail and also tried to find, next to the NR1 subunit, the glutamate/NMDA binding NR2
subunits. Immunofluorescence microscopy and western blotting were used in order to
detect the NMDA receptor on the protein level.
Primary polyclonal antibodies were purchased from Abcam (NR-1) and Santa Cruz
Biotechnology (NR-1, NR-2 A-C). The Abcam antibody binds at a cytoplasmatic region,
whereas all selected Santa Cruz Biotechnology antibodies bind extracellularly.
4.1.1 Western blot analysis of the NMDA receptor subunits
Primary antibodies from Santa Cruz Biotechnology were chosen for western blotting, since
they should work for immunofluorescence microscopy as well as western blot analysis,
according to the supplier´s information. Moreover, lysates of the human (NR-2B) and
mouse (NR-2A, NR-2C) cerebellum were used as a positive control for specific NR-2
subunits. Western blot analysis were performed using the protocol described in materials
and methods (3.5.5).
Figures 4.1.1-1.3 show the western blot results for the presence of NMDAR subunits NR-
1, NR-2 A-C in ECV304 cells. Therefore two different lysates were used as samples for
this experiment. One lysate (in figures sample mostly A or E, in figure 4.1.3 it is B) was
gained of ECV304 cells cultured on the surface of a 6-well plate (P149, 8th generation in
PBMEC-FIB growth medium), the second lysate (in figures sample C or G) is from
ECV304 cells cultured on an Transwell insert of an 6-well plate (P156, 15th generation in
PBMEC-FIB growth medium).
Actually a band of the NR-1 subunit was assumed at a molecular weight of 115 kDa, but
only the positive control seems to have such a band in this area. However, many other
bands at lower molecular weights of our samples matched to bands of the mouse
cerebellum sample, thus some sort of degradation during sample preparation is assumed.
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Bands of NR-2A were visible in both ECV304 samples close to the expected molecular
weight of 177 kDa (Fig. 4.1.2 [A, C]), but no band was seen in this area in the positive
control (Fig. 4.1.2 [B]). However, strong bands were seen at same lower molecular weights
both in samples as well as in the positive control. No bands were visible in the human
cerebellum (Fig. 4.1.2 [D]), indicating, that no NR-2A subunits had been expressed there.
The expected molecular weight of the NR-2C subunit is 135 kDa. However, according
bands were only found in one of the two samples (Fig. 4.1.2 [G]) and slightly in the
positive control (Fig. 4.1.2 [F]). The positive control showed a strong band at a molecular
weight of ~72 kDa, which matched to a band of the same sample [G]. Strong bands were
found for NR-2C in the positive control, although these fragments possessed a distinct
lower molecular weight, which matched to bands at the same height of our samples. As
already mentioned for the NR-1 subunit, some sort of degradation during our working
process was suggested. Differences between the two different samples were also seen
when we checked for NR-2C subunits. This we assume was maybe due to slightly different
culture conditions of the ECV304 cells before they were lysed.
Somehow the image of the NR-2B subunit (figure 4.1.3) was blurred and western blot
repeats showed similar results. Unfortunately, no clear bands could be seen at 178 kDa,
where the molecular weight for NR-2B was expected. But again, bands lower than 72 kDa
could be seen in the positive control [A] as well as in two different samples [B/C] and in
the mouse cerebellum [D] indicating that the primary antibody probably targeted a
degraded fragment of the NMDA receptor.
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Fig. 4.1.1: Western blot analysis of the expression of NMDA NR-1 in two different samples of ECV304 cells
[A, C]. Lysate of the mouse cerebellum was used as a positive control [B].
Fig. 4.1.2: Western blot analysis of the expression of NMDA NR-2A and –2C in two different ECV304
samples [A/E and C/G]. Lysate of the mouse cerebellum [B/F] was used as a positive control for NR-2A and
–2C, also human cerebellum lysate was checked for NR-2A.
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Fig. 4.1.3: Western blot analysis of the expression of NMDA NR-2B in two different samples [B/C].
Moreover, the lysate of a human cerebellum was used as one positive control [A] and a lysate of the mouse
cerebellum as a second positive control [D].
4.1.2 Immunofluorescence microscopic analysis of the NMDA receptor subunits
Two different protocols, described in materials and methods were used for the staining, but
it was decided to present only the results of the protocol with paraformaldehyde due to
comparability reasons. Intensity of the fluorescence signals were detected for propidium
iodide at level 2 with an exposure time of 2/3 seconds and for the NR-subunits at level 3
with an exposure time of 4 seconds.
Figures 4.1.4-4.1.8 show the immunofluorescence images after Triton-X 100
permeabilisation for NMDA subunits NR-1, NR-2A – 2C. For NR-1 stainings two
antibodies from different sources were compared. Also according blank images with only
the secondary antibody were shown in the figures in order to facilitate the comparison and
to show the significant stainings for NMDA-subunits. Cells were seeded at a density of
80,000 cells/cm² and cultured for 10 days under optimal growth conditions with medium
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exchange every second day. Used protocol for the preparation was already described in
3.5.6.2.
Figure 4.1.4: Immunofluorescence images of NR1 subunits of ECV304 cells using the primary antibody from
Abcam [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and the merge of A and B
[C]. This could be compared to control images, where only the secondary antibody was used (green
fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.1.5: Immunofluorescence images of NR1 subunits of ECV304 cells using the primary antibody from
Santa Cruz Biotechnology [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and
the merge of A and B [C]. This could be compared to control images, where only the secondary antibody was
used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.1.6: Immunofluorescence images of NR-2A subunits of ECV304 cells using primary antibody from
Santa Cruz Biotechnology [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and
the merge of A and B [C]. This could be compared to control images, where only the secondary antibody was
used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.1.7: Immunofluorescence images of NR-2B subunits of ECV304 cells using primary antibody from
Santa Cruz Biotechnology [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and
the merge of A and B [C]. This could be compared to control images, where only the secondary antibody was
used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.1.8: Immunofluorescence images of NR-2C subunits of ECV304 cells using primary antibody from
Santa Cruz Biotechnology [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and
the merge of A and B [C]. This could be compared to control images, where only the secondary antibody was
used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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In summary, western blotting and immunofluorescence microscopy suggested the presence
of NMDAR subunits NR-1, NR-2A, -2B and possibly -2C in cell line ECV304. Their
presence is a prerequisite for further functional tests with regard to the NMDA receptor.
4.2 Measurement of the intracellular calcium level
Activation of the NMDAR leads to a permeation of calcium ions into the cell.
Consequently, one of our major aims was to measure this change of the intracellular
calcium level as a first functional parameter of the activation of the NMDA-receptor by
establishing a fluorescence method using a 96-well plate system.
4.2.1 Development of a 96 well-plate assay.
The basic principles of this assay were based on different other protocols that determine
the change in calcium level by confocal laser microscopy, flow cytometric measurement or
measurement by a multiplate reader [37, 38, 39]. Finally we decided to measure changes of
the intracellular calcium level by a 96-well plate fluorescence method since recording of
many data over a longer time interval should be possible.
4.2.1.1 Comparison of different plate reader devices
The first experiments were performed on the microplate reader Polarstar Galaxy (figure
4.2.1). Concentration-dependent signals of Fluo3-AM (1, 4, 10 µM) were best seen using
the positive control Ionomycin. However, the fluorescence intensity in general was quite
unsatisfactory (figure 4.2.1), since the intensity level did not rise above 250 fluorescence
units at the maximum gain. Neither any effect of the control, 1 mM Glutamate, nor 1 mM
Glutamate/10 µM MK801 could be seen or interpreted in the graph due to stronger up- and
downturns and the lack of any detectable differences between agonists/antagonists
compared to the control. The obtained negative fluorescence resulted of a high self-
fluorescence of cells without Fluo3-AM, whose intensity was subtracted of those ECV304
cells that were loaded with the dye. In summary due to those results we assumed that the
Polarstar Galaxy microplate reader was not appropriate for this kind of experiments.
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As a result of this two other multiplate reader from Tecan were tested that were not as old
as the Polarstar Galaxy:
• Microplate reader Tecan Infinite M200i with a monochromator
• Microplate reader Tecan GeniosPro™ with filters for specific wave-lengths.
Already the first measurement with the Tecan Infinite M200i showed that the differences
in fluorescence intensity between blank and Fluo-3-AM loaded cells could easily be more
than 100 times higher compared to the Polarstar Galaxy (figure 4.2.2). Again only the
measuring points and not the real timescale were showed due to overview reasons.
Moreover, it should be noted that gain-changes were performed after the first measuring
point in the experiment depicted in figure 4.2.2, although the test substances were just
applied and again after 18 measuring points since the absolute fluorescence was still
increasing and probably would rise over the detection limits (since the first experiments
were just tests to adjust the settings of the microplate reader and to see if the assay work
we didn´t mind changes described before). However, the concentration-dependent
differences of Fluo3-AM were seen well. Therefore it was decided, based on the
concentration-dependent effect and on different protocols, to use a concentration of 4 µM
Fluo3-AM for all following experiments, since 10 µM fluorescence dye would be maybe
an unnecessary waste of money [38, 39, 40].
Also experiments with the Tecan GeniosPro showed that the fluorescence intensity is much
higher (figure 4.2.3) compared to the Polarstar Galaxy microplate reader, indicating that
both Tecan microplate readers could be used. In the experiment depicted in figure 4.2.3
already a concentration of 4µM Fluo3-AM was used and mixed with different
combinations of Ca2+-channel agonists and/or antagonists. It should be noted that in all
experiments Ionomycin was used as positive control resulting in a quite high fluorescence
level and BAPTA as a negative control resulting in a decreased intracellular calcium level.
The actual interesting measurement changes of the intracellular calcium level by different
Ca2+-channel modulators were inbetween the controls and in a much smaller range.
In summary, it was observed that both Tecan microplate readers were able to measure the
change in intracellular calcium level over a period of time, whereby such a measuring
method could not be performed on the Polarstar Galaxy. The only differences, except little
adjustment-differences between the microplate readers, were seen by the curve-
progression. In this context, it seemed that results from the Tecan Infinite M200i oscillated
more compared to the GeniosPro.
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Fig.4.2.1: Change in intracellular calcium level. Concentration-depended differences of Fluo3-AM were only
seen with Ionomycin. After 10.440 seconds cells were lysed with 100 µL HBSS/1 % Triton-X 100 to control
the uptake of the fluorescence dye into the cell. Due to overview reasons only the measuring points were
showed, the real timescale was ignored.
Fig.4.2.2: Change in intracellular calcium level on the Tecan Infinite M200i. Concentration-dependent
differences were seen at Ionomycin, 1 mM Glutamate and 1 mM Glutamate/10 µM MK801. Timescale was
ignored and only the measuring points were showed.
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Fig. 4.2.3: Change in intracellular calcium level, performed on the Tecan GeniosPro, was detected by using 4
µM Fluo3-AM.
4.2.1.2 Influence of different cell culture durations (4, 7, 14 days)
As next step optimum cultivation times to use ECV304 cells for the assays were
investigated. Therefore, cells were seeded at a density of 50,000 cells/cm² per well of an
96-well plate and cultured in an incubator at 37° C, 5 % CO2 and 96 % humidity. In order
to find a good culture time for cell growth, the change of the intracellular calcium level by
agonists such as glutamate or NMDA with or without antagonists like MK801 or D-APV
were determined after 4, 7 or 14 days cultivation. Experiments were performed in Mg2+
free medium and test-substances were dissolved in water (glycine, glutamate, MK801, D-
APV), directly in the HBSS/Probenecid/Albumin solution (BAPTA), or DMSO
(Ionomycin) to the needed stock solutions. Afterwards experimental medium was prepared
by diluting the stocks to the needed 4x concentrations. All of those experiments were
performed on the Tecan GeniosPro at 37° C. Due to overview reasons of the diagram,
percentage of the fluorescence of the positive control Ionomycin and the negative control
BAPTA were not shown, but discussed at a later point.
Figure 4.2.4 showed the results of ECV304 cells that were cultured in a 96-well plate for 4
days. Observation by a light microscope showed that the surface area was completely
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covered with cells. However, the ECV304 cells were not so compact populated than in 96-
well plates that were cultured for 7 days or longer. This reduced culture time caused
probably the resulting fluctuating curve-progression and their high standard deviations,
where no clear differences or tendencies between agonist- with/without antagonists could
be seen.
It seems that a surface completely covered in ECV304 cells is not enough to perform this
sort of experiment. In fact, it probably also take some time until the needed transporters
were fully expressed on the surface.
Another experiment where ECV304 cells were cultured in a 96-well plate for 7 days was
performed. Observation with the light microscope revealed that the cells grew tighter
together compared to the cells that were only cultured for 4 days. Moreover it was
observed that ECV304 already developed multilayer in the wells of the 7 day cultured 96-
well plate. Figure 4.2.5 showed the results of ECV304 cells that were cultured in a 96-well
plate for 7 days. Differences between agonists with/without antagonists could clearly be
seen over a period of time, whereby the effects of those Ca2+-level modulators were
discussed at a later point (4.2.2). The graph in general showed a good curve-progression
characterised by a low standard deviation.
Figure 4.2.6 shows the curve progression of a 96-well plate that was cultured with ECV304
cells for 14 days. Before the experiment was performed the wells were observed
microscopically and a tight surface with ECV304 cells was seen which developed more
multilayer than a 7 day plate. Differences between agonists with/without antagonists that
modulate the Ca2+-level were seen. However, results were quite similar to 7 day old cells,
but bigger multilayers were developed by 14 days cultured ECV304 cells. Thus, it was
decided to perform all following experiments with cells cultivated for 7 days onto 96-well
plates.
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Fig. 4.2.4: Change in intracellular calcium level of a 96-well plate that was cultured for 4 days. Values are
expressed as means +/- SEM (n=8).
Fig. 4.2.5: Change in intracellular calcium level of a 96-well plate that was cultured for 7 days. Values are
expressed as means +/- SEM (n=8).
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Fig. 4.2.6: Change in intracellular calcium level of a 96-well plate that was cultured for 14 days. Values are
expressed as means +/- SEM (n=8).
4.2.1.3 Kinetic-like- versus steady-state-studies
Besides the steady-state studies an assay for kinetic-like experiments were developed and
performed, in order to see the influence on the intracellular calcium level directly after test-
substances were administered. The experiment is based on the protocol described in
materials and methods (3.5.7), whereby medium containing Mg2+ was always used. The
substances which were needed to perform the experiment were dissolved in water (glycine,
NMDA, D-APV), or DMSO (Ionomycine) to the needed stock solutions. Afterwards the
experimental medium was prepared by diluting the stock to the needed 4x concentrations.
All experiments were performed on the Tecan Infinite M200i at 28° C. Due to the
overview of the diagram, percentage of the fluorescence of the positive control Ionomycin
were not shown, but discussed at a later point. Although several kinetic-like experiments
were performed, only the results of a few specific were shown and their outcome was then
compared with the steady-state experiments.
Since always two rows were loaded in the same step with the fluorescence dye (as
described in materials and methods), it was supposed that those were comparable with
other rows because of similar starting conditions. The curve-progression of the first
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performed kinetik-like experiments seemed to demonstrate plausible results at the first
sight. As seen in figure 4.2.7, NMDA (10 µM) was able to increase intracellular Ca2+-level
compared to the control. Moreover, more significant effects were seen when 10 µM
NMDA was mixed with different concentrations of glycine (100, 10, 1 µM), the co-agonist
on the NMDA receptor, whereby 10 µM and 1 µM glycine seemed to have the strongest
effects. By that high expectations were put in this measurement until experiments with D-
APV, a potent and specific NMDA receptor antagonist, were performed. As seen in figure
4.2.8, 10 µM NMDA caused a higher intracellular calcium level compared to the control,
by what an activation a calcium channel like the NMDA receptor was assumed. Such a
result was already also shown in figure 4.2.7, but interestingly common concentrations of
D-APV (100, 10, 1 µM) were not able to decrease the intracellular calcium level, moreover
it seemed that the calcium level increases as lower the D-APV concentration was. This
result indicates that either no functional NMDA receptor is available on the ECV304 cell
line, or the concentration of D-APV was still too low. Though it was noticeable, that again
those values that were obtained at the same time had related curve progressions of the
intracellular calcium level (figure 4.2.7, 4.2.8), indicating adulterated results due to the
measuring method. Therefore, this experiment was repeated, whereby just the order in
which the test-substances were applied, was changed, by adding and measuring the control
as the last value. As seen in figure 4.2.9 the control had one of the highest intracellular
calcium levels, moreover it is also very close to the row (10 µM NMDA/1 µM D-APV)
that was measured at the same time. Unfortunately 10 µM NMDA/10 µM D-APV had a
high calcium level, which could be explained because of the smaller fluorescence in the
raw-data compared to the other rows, where same changes in [%] had a bigger effect.
Although all rows should be treated the same, the factor „time“ that is needed between two
pairs of rows, seems to have an important influence which adulterate the values. Due to
this outcome, kinetic-like experiments with this protocol were stopped, since the results
were questionable.
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Fig. 4.2.7: Influence of 10 µM NMDA with/without different concentrations of glycine on the intracellular
calcium level, compared to the control. Values are expressed as means +/- SEM (n=8).
Fig. 4.2.8: Change in intracellular calcium level by 10 µM NMDA with/without different concentrations of
D-APV. Values are expressed as means +/-SEM (n=8).
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Fig. 4.2.9: Influence of a different application order on the intracellular calcium level. Values are expressed
as means +/- SEM (n=8).
4.2.1.4 Influence of different tested parameters on the intracellular calcium level.
In order to optimise our fluorescence method to measure the change in intracellular
calcium level, different parameters were changed and tested.
NBS vs. Albumin: In the first experiments NBS was used instead of Albumin (usage see
materials and methods 3.5.7). In those experiments (data not shown) the control always
showed one of the highest intracellular calcium levels of all tested values. Unfortunately
the composition of the serum was not exactly known, why a change to albumin was
chosen. However, also those experiments showed that the control always had one of the
highest intracellular calcium levels. Although no differences between NBS and albumin
were seen, it was decided that only albumin would be used for all following experiments.
This decision was made due to the fact that defined concentrations of glycine and/or
glutamate should be used since the exact composition of serum is not known, leftovers of
those amino acids could still be in the serum.
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Fluo3-AM vs. Calcium-Green-AM: Since this thesis is based on the work of Kuhlmann
et al. [20] who used calcium-green as fluorescnece dye for his experiments, also this
indicator was tested in order to see possible advantages over Fluo3-AM which was
normally used. In those experiments (data not shown) Fluo3-AM showed the differences in
calcium level more precisely than Calcium-Green-AM. This was caused probably due to
the fact that the fluorescence dyes possess different KD-values. Fluo3-AM has a KD= 325
nM [41] and Calcium-Green-AM a KD=190 nM [42] at 22° C. With the higher KD-values
of Fluo3-AM bigger intracellular concentrations of calcium could be measured, whereas it
seemed that Calcium-Green-AM was faster saturated with Ca+2 .
Use of Probenecid: In order to minimise the efflux of the fluorescence dye of the cells,
Probenecid, an anion channel blocker, was also implemented in our protocol (see materials
and methods 3.5.7). Experiments where Probenecid was not used (data not shown)
revealed a significant increase in fluorescence intensity by binding of the effluxed
fluorescence dye Fluo3 with calcium in the medium. This increased leakage fits to the
information given by the product information of the fluorescence dye [41].
Experiments using HBSS with/without Mg2+: During this thesis, experiments were
performed using HBSS with/without Mg2+ due to the advice of Dr. M. Berger. The
outcome of those results will be discussed at a later point in 4.2.2.
Experiments with/without Hepes: The beneficial effects of Hepes, a buffer agent with a
buffer capacity between pH 6.8-8.2 were tested in our solutions that were needed for the
experiments. Those results revealed (data not shown) that no significant differences
between experiments with solutions consisting the buffer agent or no Hepes were seen.
Only the adjustment to pH 7.4 was a bit easier when Hepes was used. Since it was not seen
that the adjusted pH-value really changed until the experiment ends, it could be chosen
whether a buffer agent should be used or not.
Influence of shortening the loading time of Fluo3-AM to 30 minutes: In order to
minimise the experimental time and work with maybe more vital cells it was tested to
shorten the loading time of the fluorescence dye Fluo3-AM to 30 minutes instead of the
normally 60 minutes. In those results it was seen that the base fluorscence was lower
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compared to other experiments (data not shown) indicating that the uptake of Fluo3-AM
into ECV304 were lower, but expressed in percent the fluorescence units fit again to the
other results. The effects of the used test-substances will be discussed in more detail in
4.2.2. In order of a better comparison between the experiments a loading time of 60
minutes with Fluo3-AM was still maintained, although a loading of 30 minutes with the
fluorescence dye also seemed to work.
4.2.2 Influence of Ca2+-level modulators
After establishment of the 96-well plate assay to measure the intracellular calcium levels,
the influence of different Ca2+-level modulators was tested. Especially the change of
intracellular calcium level by the activation or inhibition of an active NMDA receptor
should be tested. Therefore, the steady-state-protocol described in materials and methods
(3.5.7) was used unless deviations specified at the single experiment descriptions.
4.2.2.1 NMDA receptor modulators
Following the protocol described in 3.5.7, all experiments with NMDA receptor
modulators were finally performed in Mg2+- and Ca2+-free HBSS (6648) supplemented
with Ca2+. In this context it should be noted, that the fluorescence-dye solution for loading
the ECV304 cells with Fluo3-AM was prepared with HBSS (4641) containing Mg2+- and
Ca2+. The substances tested were dissolved in water (glycine, glutamate, NMDA, MK801,
D-APV), directly in the HBSS/Probenecid/Albumin solution (BAPTA), or DMSO
(Ionomycin, Verapamil) to the needed stock concentrations. Afterwards the experimental
medium was prepared by diluting the stock solutions to the needed 4x concentration. Since
the NMDA receptor also needs glycine as a co-agonist to be activated, it should be noted
that in every solution must also be an appropriate final-concentration of it (10 µM glycine
in our case). Experiments were performed on the Tecan GeniosPro at 37° C. Due to
presentation reasons, Ionomycin and BAPTA curves were not completely shown in the
graphs.
The influence of different glutamate concentrations (1 mM, 0.3 mM, 0.1 mM, 0.01 mM)
on the intracellular calcium level and the change over a period of time was shown in figure
4.2.10. Different concentrations of glutamate displayed varying intracellular calcium level.
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1 mM glutamate seemed to cause the highest intracellular calcium level which decreased at
lower glutamate concentrations. Unfortunately the effects of 100 µM MK801 alone (in
combination with 10 µM glycine, the co-agonist which was always present) were tested in
order to see the influence on the intracellular calcium level, instead of a control-value.
However, interestingly also MK801 alone was able to reduce the intracellular calcium
level to nearly the same level as glutamate (and glycine) supplemented with the channel
blocker MK801 did. Actually no big effect on the intracellular calcium level of the NMDA
receptor blocker MK801 alone was assumed, since the receptor should only be activated by
agonists like glutamate or NMDA in combination with the co-agonist glycine and not by
glycine and MK801 alone. A retry of nearly the same experiment was carried out in order
to check the influence of different glutamate concentrations (3 mM, 1 mM, 300 µM, 100
µM) on the intracellular calcium level, compared to a control-value (see figure 4.2.11a).
Interestingly, a concentration-dependent effect, as it was seen in figure 4.2.10, could not be
observed, instead all glutamate-values without the inhibitor MK801 had nearly the same
intracellular calcium level. However, again all the values were glutamate was applied
together with MK801 showed a lower intracellular calcium level. The differences between
the endpoints of the glutamate-values and the glutamate/MK801-values compared to the
control that is set to 100% were seen in the bar graph 4.2.11b. In both experiments
Ionomycin displayed a fluorescence of about 445 % (4.2.10) and 413 % (4.2.11) and
BAPTA of 75 % (4.2.10) and 82 % (4.2.11) after addition of the substances.
Figure 4.2.12a shows different concentrations of NMDA (3 mM, 1 mM, 300 µM, 100 µM,
30 µM, 10 µM) which were tested in order to see their influence on the intracellular
calcium level. Again, controls exhibited highest intracellular calcium levels over a period
of time, as it was already observed in the experiments were glutamate was added (see
4.2.11a). However, the effect of NMDA seemed more interesting, since the intracellular
calcium level decreased at higher the NMDA concentrations.
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Fig. 4.2.10: Influence of different concentrations of glutamate on the intracellular calcium level. This effect
could partially be inhibited by 100 µM MK801. ECV304 cells were used at passage 178. Values are
expressed as means +/- SEM (n=8).
Fig. 4.2.11a: Repeat of the experiment about the influence of different concentrations of glutamate on the
intracellular calcium level. ECV304 cells were used at passage 189. Values are expressed as means +/- SEM
(n=8).
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Fig. 4.2.11b: Difference between varying concentrations of glutamate with/without 100 µM MK801
compared to the control after 33 minutes. Control values were set to 100 %. Values are expressed as means
+/- SEM (n=8).
This was the completely opposite effect that was once observed in a glutamate experiment
(see 4.2.10) and expected if the NMDA receptor was the main target of glutamate to
increase the intracellular calcium level. Since the intracellular calcium level decreases as
higher the NMDA concentration got, some sort of a strong counter-regulation, activated by
the increasing NMDA concentration and the resulting overstimulation of the NMDA
receptor, could be assumed. Interestingly, significant increasing of the NMDA
concentration was necessary, since the concentration range between 10 µM–100 µM
caused no detectable effects. However, NMDA is also said to be a specific agonist on the
NMDA-receptor, whereby seen effects were assigned to NMDA receptor activation. The
concentration-dependent effect of this experiment at the endpoint is shown in a bar graph
in more detail (figure 4.2.12b). Quite interesting was also the effect of 3 mM NMDA since
these concentrations seems to have a big influence on the intracellular calcium level. Those
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values showed even a lesser intracellular calcium level than the values of 300 µM
NMDA/100 µM MK801, whereas 3 mM NMDA/100 µM MK801 once more was lower
than 3 mM NMDA alone. However, in this context the difference between agonist
with/without inhibitor was bigger at the 300 µM NMDA concentration than it was
observed at 3 mM NMDA concentration.
Fig. 4.2.12a: Influence of different NMDA concentrations partly with the channel blocker MK801 on the
intracellular calcium level. ECV304 cells were used at passage 188. Values are expressed as means +/- SEM
(n=8).
8 5
9 0
9 5
1 0 0
1 0 5
1 1 0
1 1 5
1 2 0
1 2 5
1 3 0
1 3 5
-5 0 0 0 5 0 0 1 0 0 0 1 5 0 0 2 0 0 0
M e a s u r in g  p o in ts  [s e c ]
F
lu
o
re
s
c
e
n
c
e
 [
%
]
C o n tro l
Io n o m yc in
B AP T A
3  m M  N M D A
1  m M  N M D A
3 0 0  µM  N M D A
1 0 0  µM  N M D A
3 0  µM  N M D A
1 0  µM  N M D A
3  m M  N M D A/1 0 0  µM  M K 8 0 1
3 0 0  µM  N M D A/1 0 0  µM  M K 8 0 1
74
Fig. 4.2.12b: Difference between varying endpoint-concentrations of NMDA with/without the channel
blocker MK801 compared to the control after 33 minutes. Control values were set to 100 % Values are
expressed as means +/- SEM (n=8).
The experiment shown in figure 4.2.13a was already partly described in section 4.2.1,
because of the influence of shortening the loading time of Fluo3-AM to 30 minutes. Now,
the influence of the tested substances of this experiment on the intracellular calcium level
will be presented. 1 mM glutamate was tested with/without different concentrations of the
NMDA receptor channel blocker MK801. Moreover a pre-test with 100 µM Verapamil
was performed. Figure 4.2.13a shows the results of this experiment, in which again the
control had probably the highest intracellular calcium level over a period of time.
Application of 1 mM glutamate did not change the intracellular calcium levels compared to
the control (as it was once seen in 4.2.10). However, the goal of this experiment was to
check a possible concentration-dependent effect of the NMDA receptor channel blocker
MK801 onto the NMDA receptor activity, which should have been activated by the
simultaneous addition of 1 mM glutamate and 10 µM glycine. As expected, different
concentrations of MK801 showed in combination with 1 mM glutamate (and glycine)
80
85
90
95
100
105
Co
ntr
ol
10
 µM
 N
MD
A
30
 µM
 N
MD
A
10
0 µ
M 
NM
DA
30
0 µ
M 
NM
DA
1 m
M 
NM
DA
3 m
M 
NM
DA
30
0 µ
M 
NM
DA
/10
0 µ
M 
MK
80
1
75
varying intracellular calcium level, in which the highest concentration of the channel
blocker resulted in the lowest observed intracellular calcium level. For a better overview,
the endpoint-concentration of this experiment was also shown in a bar graph (4.2.13b). In
this experiment also a pre-test with 100 µM Verapamil, a L-type calcium channel blocker,
was accomplished since the high intracellular calcium levels of the control value was
probably cause of a different Ca2+-channel. In this experiment Ionomycin was again used
as a positive control reaching an average fluorescence of about 372 % and BAPTA as
negative control decreasing average fluorescence intensity to 55 % compared to the
control.
Fig. 4.2.13a: Change of the intracellular calcium level caused by different concentrations of the NMDA-
receptor channel blocker MK801. ECV304 cells were used at passage 180. Values are expressed as means
+/- SEM (n=8).
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Fig. 4.2.13b: Difference between varying endpoint-concentrations of 1 mM glutamate with/without the
channel blocker MK801 compared to the control after 39 minutes. Control values were set to 100 %. Values
are expressed as means +/- SEM (n=8).
The influence of 100 and 10 µM NMDA with/without 100 µM D-APV on the intracellular
calcium levels and the change over a period of time was shown in figure 4.2.1.14a. The
experiment was performed with ECV304 cells that were cultured for 14 days. This was
already partly described in 4.2.1.2. The results showed that 100 µM D-APV was not able
to lower the intracellular calcium level in any possible set-up compared to the control. This
was somehow already expected due to the lack of effects during the kinetic-like
experiments. However, further studies in our group showed that D-APV influenced the
intracellular calcium level signifacant at higher concentrations of 1 to 3 mM. These high
concentrations were not tested in this diploma thesis since literature based data indicated
that D-APV effects should have been detactable at maximum 100-300 µM interacting with
a functional NMDA-receptor. As expected also NMDA did not show any distinct effects
on the intracellular calcium level at the used concentrations. For a better overview, calcium
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concentration at the endpoint of this experiment were also shown in a bar graph (4.2.14b).
It should also be mentioned that the glutamate values which were also performed during
this experiment (see graph from 4.2.1.2) were not shown here. In this experiment
Ionomycin was again used as a positive control reaching an average fluorescence of about
334 % and BAPTA as negative control decreasing average fluorescence intensity to 53 %
compared to the control.
Fig. 4.2.14a: Influence of NMDA with/without D-APV on intracellular calcium levels. ECV304 cells were
used at passage 178. Values are expressed as means +/- SEM (n=8).
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Fig. 4.2.14b: Difference between varying endpoint-concentrations of NMDA with/without D-APV compared
to the control after 51 minutes. Control values were set to 100 %. Values are expressed as means +/- SEM
(n=8).
4.2.2.2 Acetylcholine as calcium modulator
Following the protocol described in 3.5.7, all experiments with NMDA receptor
modulators were finally performed in Mg2+- and Ca2+-free HBSS (6648) supplemented
with Ca2+. In this context it should be noted, that the fluorescence-dye solution for loading
the ECV304 cells with Fluo3-AM was prepared with HBSS (4641) containing Mg2+- and
Ca2+. Different concentrations of acetylcholine were tested in this experiment, although a
direct link between acetylcholine, or acetylcholine-receptors and the NMDA receptor is not
obvious at the first sight. However, the influence of MK801 on nicotinic acetylcholine
receptors (nAchR) was already reported [43] and since neuronal nAchR could also be
permeable for Ca2+ it was decided to investigate a possible influence of acetylcholine on
the intracellular Ca2+ level. The substances were dissolved in water (acetylcholine,
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MK801), directly in the HBSS/Probenecid/Albumin solution (BAPTA), or DMSO
(Ionomycin) to the needed stock solutions. Afterwards the experimental medium was
prepared by diluting the stock solutions to the needed 4x concentrations. Since the NMDA
receptor was not the target in this experiment, it should be noted that no glycine was added
as it was done during the experiments described in 4.2.2.1. Tests were performed on the
Tecan GeniosPro at 37° C. Due to overview reasons fluorescence percentage of Ionomycin
and BAPTA were not shown in the following graph. However, the positive control
Ionomycin showed an increased fluorescence of 332 % (4.2.14a) or 392 % (4.2.14b) and
the negative control BAPTA a of 52 %(4.2.14a) or 64 % (4.2.14b) after addition of the
substances.
Since the functionality of the NMDA receptor as a Ca2+ channel in ECV304 cells is yet not
fully confirmed, the influence of different concentrations of acetylcholine (0.001, 0.01, 0.1,
1, 10, 100 µM) on the intracellular calcium level compared to MK801 were tested in Mg2+-
free and Mg2+-containing HBSS. The first experiment was performed in HBSS (4641) with
Mg2+ and interestingly no effects or differences compared to the control could be seen. As
in probably every performed experiment, the control had again one of the highest
intracellular calcium levels over the period of time. Also the tested concentrations of
acetylcholine nearly had the same curve progression as it was observed for the control
indicating maybe no influence of Ach onto total intracellular calcium values.
80
Fig. 4.2.14a: Influence of different concentrations of acetylcholine on the intracellular calcium level in HBSS
with Mg2+ and Ca2+, compared with 100 µM MK801 alone or in combination with 1 µM Ach. ECV304 cells
were used at passage 186. Values are expressed as means +/- SEM (n=8).
Fig. 4.2.14b: Influence of different concentrations of acetylcholine on the intracellular calcium level in Mg2+-
and Ca2+-free HBSS supplemented with Ca2+ compared with 100 µM MK801 alone or in combination with 1
µM Ach. ECV304 cells were used at passage 187. Values are expressed as means +/- SEM (n=8).
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Fig. 4.2.14c: Difference between varying endpoint-concentrations of Ach and MK801 in Mg2+-containing
(blue) or Mg2+-free (green) HBSS-solutions compared  to the control after 33 minutes (blue) and 39 minutes
(green). Control values were set to 100 %. Values are expressed as means +/- SEM (n=8).
However, interestingly no effect of 100 µM MK801 on the intracellular calcium level was
detected using Mg2+-HBSS. Compared to experiments before, where only glycine and
Mg2+ was not added. Since glycine was not assumed to modulate the intracellular calcium
level alone the same test with acetylcholine was repeated in Mg2+-free HBSS
supplemented Ca2+. The results revealed (figure 4.2.14b) that the control had one of the
highest intracellular calcium level. Comparable to the experiment presented in figure
4.2.14a, acetylcholine seemed to have no detectable effect also in Mg2+-free medium. Only
100 µM acetylcholine could have shown a little effect, but due to the big standard
deviation this wasn´t significant. Perhaps following experiments should use increased
concentrations of acetylcholine to investigate whether effects could be detected at higher
acetylcholine concentrations. However, 100 µM MK801 was again able to decrease the
intracellular calcium level, which confirmed that Mg2+ free HBSS was necessary to detect
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MK801 dependent changes in intracellular Ca2+. For a better overview the endpoints of the
different calcium concentrations were showed by a bar graph (see 4.2.14c) and the
outcome of both experiments (blue = solutions with Mg2+ and Ca2+, green = solutions with
Ca2+ and without Mg2+) could be compared with each other.
4.2.2.3 Bay-K 8664 and Verapamil as calcium modulators
Based on the protocol described in 3.5.7, the following described experiments were finally
performed in Mg2+- and Ca2+-free HBSS (6648) supplemented with Ca2+. In this context it
should be noted, that the fluorescence-dye solution for loading the ECV304 cells with
Fluo3-AM was prepared with HBSS (4641) containing Mg2+- and Ca2+. Different
concentrations of (S)-(-)-BayK 8664, a L-type Ca2+-channel activator, with/without the the
L-type channel blocker Verapamil were the main tested substances in following described
experiments in order to investigate their influence on the intracellular calcium level. The
substances were dissolved directly in the HBSS/probenecid/Albumin solution (BAPTA), or
DMSO (Ionomycin, BayK 8644, Verapamil) to the needed stock solutions. Afterwards the
experimental medium was prepared by diluting the stock to the needed 4x concentrations.
Since the NMDA-receptor was again not the assumed target in these experiments, glycine
was not added as it was done during the experiments described in 4.2.2.1 Experiments
were performed on the Tecan GeniosPro at 37° C. Due to the overview reasones
percentage of Ionoycin and BAPTA were not shown in the graphs. However, the positive
control Ionomycin reached a fluorescence of 443 % (4.2.15a) or 408 % (4.2.15b) and the
negative control BAPTA showed fluorescence percentages of 61 %(4.2.15a) or 63 %
(4.2.15b).
Since the L-type channel blocker Verapamil already showed to decrease the intracellular
calcium level (figure 4.2.13a) and the cause of the increasing Ca2+ inside of the ECV304
cells of the control values was still unclear, the L-type Ca2+-channel activator (S)-(-)-BayK
8664 was chosen as an additional assumed positive control which targets another Ca2+-
channel than the NMDA receptor. Figure 4.2.15a shows the effects on the intracellular
calcium level observed after addition of 0.01, 0.1, 1, 10 µM BayK 8664 with/without 100
µM Verapamil in HBSS-solutions containing Mg2+ and Ca2+. All values showed a time-
dependent increase in the intracellular calcium level, but compared to the control the
curves were quite similar or slightly decreased in case of higher concentrations of BayK
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8664. This effect of BayK 8664 could be partially blocked by addition of 100 µM
Verapamil. Nearly the same experiment was repeated with the only difference that HBSS-
solution without Mg2+ was used. Tested concentrations of BayK 8664 were changed to 0.1,
1, 10, 100 µM in order to investigate a possible stronger concentration dependent effect.
As it was assumed, the highest concentration of BayK 8664 (100 µM) caused the lowest
intracellular calcium level over a period of time again. Interestingly, at the initial
measuring phase 100 µM BayK seemed to cause nearly no change in intracellular calcium
level which was then stable over the whole measuring period. In contrast to this, 100µM
BayK supplemented with 100 µM Verapamil showed a higher starting point after
substance application which decreased rapidly to a similar calcium level as it was seen
with 100 µM BayK only. These differences in the initial phase maybe reflected a
regulatory phase in which intracellular Ca2+ were adjusted. As it was already seen in the
experiments with Mg2+/Ca2+ containing HBSS-solutions, similar curve-progressions of 0.1
µM and 1 µM BayK were observed compared to the control, whereas 10 µM BayK
showed a decreased intracellular calcium level. When 100 µM Verapamil were added in
combination with BayK, the intracellular calcium levels were again lower compared to the
values without Verapamil. For a better overview the fluorescence-endpoints of both
experiments were presented as a bar graph (4.2.15c).
Fig. 4.2.15a: Influence of different concentrations of BayK 8664 with/without 100 µM Verapamil on the
intracellular calcium level in solutions containing Mg2+. ECV304 cells were used at passage 184. Values are
expressed as means +/- SEM (n=8).
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Fig. 4.2.15b: Infence of different concentrations of BayK 8664 with/without 100 µM Verapamil on the
intracellular calcium level in solutions without Mg2+. ECV304 cells were used at passage 182. Values are
expressed as means +/- SEM (n=8).
Fig. 4.2.15c: Difference between varying endpoint-concentrations of BayK 8664 with/without 100 µM
Verapamil in Mg2+-containing (blue) or Mg2+-free (green) HBSS-solutions after 39 minutes. Values are
expressed as means +/- SEM (n=8).
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4.2.2.4 Influence of a plasma membrane Ca2+-ATPase modulator and inhibition of the
Ca2+-release from the sarcoplasmatic reticulum
Based on the protocol described in 3.5.7, the following described experiment was
performed in HBSS (4641) containing Mg2+ and Ca2+. The substances were dissolved in
water (glutamate, glycine), EtOH (Ryanodine), directly in the HBSS/Probenecid/Albumin
solution (BAPTA, Methyl-ß-Cyclodextrine), or DMSO (Ionomycin) to the used stock
solutions. Afterwards the experimental medium was prepared by diluting the stock
solutions to the needed 4x concentrations. Since the NMDA-receptor was also targeted,
glycine was needed and added to every solution (final concentration 10 µM glycine). After
cells were loaded with the Fluo3-AM-solution, defined wells were pre-incubated with 75
µL of a 10 mM or 50 mM methyl-ß-cyclodextrin-solution at 37 °C for 30 minutes (=same
pre-incubation step as described in the methods). Notedly, methyl-ß-cyclodextrine was
added in single pipetting steps to the wells after the baseline was measured. Experiment
was performed on the Tecan GeniosPro at 37° C. Due to overview reasons percentage of
the fluorescence of Ionomycin and BAPTA were not shown. However, the positive control
Ionomycin raised to a fluorescence of 352 % and the negative control BAPTA yielded a
fluorescence of 82 %.
Since almost every experiment showed a high intracellular calcium level of the control
values over the period of time, tests about the Ca2+-release from intracellular stores and the
effect of blocking the plasma membrane Ca2+-ATPase by Ryanodine were carried out. The
result of this experiment is shown below (figure 4.2.15a). No significant differences
between the values with Ryanodine and glutamate with/without each other were detected
compared to the control. Every value with Ryanodine except those with 1 mM glutamate
had a lower intracellular calcium level compared to the control. This could be interpreted
as a little tendency. However, no effect of glutamate on the intracellular calcium level
could be observed. Interestingly the pre-incubation with methyl-ß-cyclodextrine had
already a high influence on the absolute values of the base fluorescence at the starting
point (figure 4.2.16b). Moreover, addition of 25 µL (to reach a total volume of 100 µL
each well) of the single concentrated methyl-ß-cyclodextrin-solutions even increased this
effect, although the difference in the absolute fluorescence could not be recognised when
the values were presented as percentages (figure 4.2.16a). 50 mM methyl-ß-cyclodextrin
even nearly reaches the same fluorescence values as it was observed for the positive
control Ionomycin. This effect is probably caused due to the block of the PMCA by
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dissolution out of the membrane. Further disintegration of the membrane maybe enables
free calcium entry into the cells. For a better overview the fluorescence-endpoints of the
absolute values were also presented as a bar graph (4.2.16c).
Fig. 4.2.16a: Influence of different concentratins of Ryanodine or methyl-ß-cyclodextrine with/without 1 mM
glutamate compared to a control or 1 mM glutamate alone. ECV304 cells were used at passage 190. Values
are expressed as means +/- SEM (n=8).
Fig. 4.2.16b: Absolute values of the experiment already seen in figure 4.2.16a, whereas the influence of the
preincubation with methyl-ß-cyclodextrin could not be seen there. ECV304 cells were used at passage 190.
Values are expressed as means +/- SEM (n=8).
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Fig. 4.2.16c: Difference between varying endpoint-concentrations of the absolute values of 1 mM glutamate
with/without different concentrations of Ryanodine or Methyl-ß-cylcodextrine compared to the control after
33 minutes. Control values were set to 100 %. Values are expressed as means +/- SEM (n=8).
4.3 Recheck for presence of the NMDA receptor in the cell
membrane by immunofluorescence microscopy in cell line
ECV304
4.3.1 Immunofluorescence images of non-permeabilized ECV304 cells
Although western blotting and immunofluorescence microscopy already suggested
presence of NMDAR subunits in cell line ECV304, the lack of an increased intracellular
calcium by agonists as glutamate or NMDA indicated probably a receptor, which is not
functionally active. Therefore immunofluorescence microscopy was performed again in
order to ensure the presence and to investigate the localisation of NDMA receptor subunits
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in our cell line. Since many antibodies target protein domains which are located in the
cytoplasma, a permeabilization of the cell’s membrane is necessary to enable the contact to
the antibody’s target. However, next to the Abcam antibody for the NR-1 subunit
(ab52177), we also purchased antibodies from Santa Cruz Biotechnology binding
fragments of the NMDAR subunits which are located extracellularly. For these antibodies
no permeabilization is needed in the first place. The recheck for the presence of the NMDA
receptor should provide a better understanding if the NMDAR subunits are expressed on
the surface of ECV304 cells. The used protocol is described in materials and methods,
whereby the permeabilization step was not carried out. Intensity of the fluorescence signals
were detected for Propidiumiodide at level 2 with an expsure time of 4 seconds and for the
NR-subunits at level 3 with an exposure time of 6 seconds. The increased exposure time
for Propidiumiodide was necessary for non-permeabilized cell layers, because this
substance is generally excluded from viable cells, but can easily penetrate into dead (or
permeabilized) cells.
Figures 4.3.1-4.3.6 show the immunofluorescence images for NMDA subunits NR-1, NR-
2A – 2C of non permeabilised ECV304 cells. For NR-1 stainings the Abcam antibody was
compared to the one obtained from Santa Cruz. Also according blank images with only the
secondary antibody were shown in the figures in order to facilitate the comparison and to
point out to significant stainings for NMDA-subunits. Cells were seeded at a density of
80,000cells/cm² and cultured for 10 days under optimal growth conditions with medium
exchange every second day. Used protocol for the preparation was already described in
3.5.6.2.
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Figure 4.3.1: Immunofluorescence images of NR1 subunits of ECV304 cells using primary Abcam antibody
[A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and the merge of A and B [C].
This could be compared to control images, where only the secondary antibody was used (green fluorescence
[D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.2: Immunofluorescence images of NR1 subunits of ECV304 cells using primary Santa Cruz
Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and the
merge of A and B [C]. This could be compared to control images, where only the secondary antibody was
used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.3: Immunofluorescence images of NR-2A subunits of ECV304 cells using primary Santa Cruz
Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and the
merge of A and B [C]. This could be compared to control images, where only the secondary antibody alone
was used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.4: Immunofluorescence images of NR-2B subunits of ECV304 cells using primary Santa Cruz
Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and the
merge of A and B [C]. This could be compared to control images, where only the secondary antibody alone
was used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.5: Immunofluorescence images of NR-2C subunits of ECV304 cells using primary Santa Cruz
Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as control [B] and the
merge of A and B [C]. This could be compared to control images, where only the secondary antibody alone
was used (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.6: Immunofluorescence images of non permeabilized NR-1 subunits of ECV304 cells using
primary Santa Cruz Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as
control [B] and the merge of A and B [C]. This was compared with images of permeabilized ECV304 cells
with the same antibody (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.7: Immunofluorescence images of non permeabilized NR-2A subunits of ECV304 cells using
primary Santa Cruz Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as
control [B] and the merge of A and B [C]. This was compared with images of permeabilized ECV304 cells
with the same antibody (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.8: Immunofluorescence images of non permeabilized NR-2B subunits of ECV304 cells using
primary Santa Cruz Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as
control [B] and the merge of A and B [C]. This was compared with images of permeabilized ECV304 cells
with the same antibody (green fluorescence [D], cell nuclei [E], merge of D and E [F]).
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Figure 4.3.9: Immunofluorescence images of non permeabilized NR-2C subunits of ECV304 cells using
primary Santa Cruz Biotechnology antibody [A], with the appropriate cell nuclei stain (propidium iodide) as
control [B] and the merge of A and B [C]. This was compared with images of permeabilized ECV304 cells
with the same antibody (green fluorescence [D], cell nuclei [E], merge of D and E [F]). Although a smaller
fluorescence
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4.3.2 Attempt to induce NMDA receptor expression on the surface of ECV304 cells
by a pre-stimulation with 1 mM glutamate
Since previous experiments suggested that the NMDA receptor is mostly located in the
cytoplasm of the cells, ECV304 cells were pre-incubated on cover slips with 1 mM
glutamate for 30 minutes. The idea was that the stimulation should increase the presence of
the intracellular found fragments on the surface of the cell. This was then investigated by
immunofluorescence microscopy. This pre-incubation was made, since stimulation may
lead to an increased shuttling of the receptor to the surface in order to interact with the
agonist.
Intensity of the fluorescence signals of non-permeabilized cell layers was detected for
Propidiumiodide at level 3 with an exposure time of 2 seconds and for the NR-subunits at
level 3 with an exposure time of 4 seconds. The increased exposure time and the higher
fluorescnece intensity level of Propidiumiodide avowed itself by the fact that this
substance is generally excluded from viable cells, but can easily penetrate into dead cells.
Figures 4.3.10 and 4.3.11 show the immunofluorescence images of non permeabilized
ECV304 cells. Thereby a normal prepared image of the NR-1 subunit (Fig. 4.4.1) is
compared to an image (4.4.2) where the cover slips were pre-incubated with 1 mM
glutamate for 30 minutes. Also according blank images with only the secondary antibody
were shown in the figures in order to facilitate the comparison and to show the significant
stainings for NMDA-subunits. Cells were seeded at a density of 80,000cells/cm² and
cultured for 10 days under optimal growth conditions with medium exchange every second
day. Used protocol for the preparation was already described in 3.5.6.2.
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Figure 4.3.10: Immunofluorescence images of NR-1 subunits of ECV304 cells which were not stimulated für
with 1 mM glutamate for 30 minutes. Used primary Santa Cruz Biotechnology antibody [A], with the
appropriate cell nuclei stain (propidium iodide) as control [B] and the merge of A and B [C]. This could be
compared to control images, where only the secondary antibody alone was used (green fluorescence [D], cell
nuclei [E], merge of D and E [F]).
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Figure 4.3.11: Immunofluorescence images of NR-1 subunits of cells which were pre-incubated with 1 mM
glutamate for 30 minutes. Used primary Santa Cruz Biotechnology antibody [A], with the appropriate cell
nuclei stain (propidium iodide) as control [B] and the merge of A and B [C]. This could be compared to
control images, where only the secondary antibody alone was used (green fluorescence [D], cell nuclei [E],
merge of D and E [F]).
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It was assumed that these slight differences in fluorescence could also be due to unspecific
binding extracellularely. Moreover, the fluorescence intensity of images with
permeabilized ECV304 cells from chapter 4.1.2 were even stronger compared to the non-
permeabilized ones (see figures 4.3.6 – 4.3.9).For a better comparison those images were
also presented with the same fluorescence intensity ( propidium iodide at level 2, NR-
subunits at level 3) and the same exposure time (propidium iodide for 2/3 seconds, NR-
subunits for 4 seconds). This indicates that NMDA receptor subunits are mostly expressed
and located in the cytoplasma in our ECV304 cell line.
Therefore an experiment was performed to induce NMDAR-subunit expression on the
surface of ECV304 cells by a pre-incubation step with 1 mM glutamate. These images
showed that some cells were sensitive to 1 mM glutamate and induced NR-1 subunit
expression on the surface of ECV304 cells. However, if this induced binding of the
primary antibody could also be related to an increased NMDAR functionality is still
unclear.
4.4 Influence of 1 mM glutamate with or without 10 µM
MK801 on the transendothelial electrical resistance (TEER)
Several groups have recently shown that increased glutamate is able to decrease the barrier
integrity of BBB in vitro models [18,20]. It was suggested that the decrease of TEER was
mediated by the NMDAR, since NMDAR antagonist MK801 was able to block these
effects. Since no significant increase of the intracellular calcium level as well as no
expression of the NMDA receptor on the surface were found, no decrease of TEER could
have been expected based on these data. In order to assess the influence of glutamate on
the integrity of the BBB model, cells were seeded on collagen-coated 6 well Transwell
inserts and were cultured for 14 days. Figure 4.4.1 shows the effects of 1 mM glutamate
with or without 10 µM MK801 and the appropriate controls. Interestingly, these
experiments confirmed previously published data from other research groups. 1 mM
glutamate decreased the TEER in a time-dependent manner in serum and heparin free
medium. This negative effect was slightly prevented by 10 µM of the NMDAR-antagonist
MK801 during the exposure time of 3 hours. After the 3 hour exposure, the medium was
changed to normal serum and heparin free growth medium for another 21 hours. After 24
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hours TEER was still decreased after the glutamate treatment, whereas addition of MK801
to the glutamate during prior treatment was able to restabilize the BBB within this time-
frame. Interestingly, these effects were only detected in serum and heparin free medium,
but not in basic growth medium containing serum and heparin. This could be a hint for
serum and/or heparin BBB stabilising effects during glutamate treatment.
Fig. 4.4.1: Loss of TEER by 1 mM glutamate exposure over a period of time. Addition of 10 µM MK801
was able to reduce this effect. Values are expressed as means +/- SEM (n=3).
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4.5 Influence of 1 mM glutamate with/without 10 µM MK801
on specific protein-expressions
As described in materials and methods (3.5.4-3.5.5), cells grown on Transwell inserts were
treated with 1 mM glutamate with/without 10 µM MK801 for 3 hours, then the
experimental medium was removed, refilled with serum- and heparin- free C6-medium and
incubated for another 21 hours. These treatments led partly to decreased TEER values. In
order to investigate the effects onto the expression levels of several proteins, western blots
were carried out. Prior to subsequent western blot analysis, cells were lysed and protein
concentrations were determined by a Bradford protein assay.
Tight junction proteins (Occludin, ZO-1):
Figure 4.5.1 shows the influence of 1 mM glutamate with/without 10 µM MK801 on the
protein expression of occludin and ZO-1 compared to the control. Thereby 1 mM
glutamate was able to reduce the amount of total occludin level compared to the control.
Even addition of 10 µM MK801 was not able to reduce this glutamate-induced down-
regulation.
The tight junction protein ZO-1 showed other effects compared to occludin. Here, 1 mM
glutamate seemed to induce a small increase in the total ZO-1 protein level. However, on
the other hand 1 mM glutamate with 10 µM MK801 induced ZO-1 expression in ECV304
cells, by what partially protection of the BBB could be assumed.
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Fig. 4.5.1: Influence of 1 mM glutamate with/without 10 µM MK801 on the total protein level of Occludin
and ZO-1. C = Control, G = 1 mM glutamate, M = 1 mM glutamate/10 µM MK801. Values are expressed as
means +/- SEM (n=2).
Efflux transporter proteins (P-gP, MRP-1):
In figure 4.5.2 the influence of 1 mM glutamate with/without 10 µM MK801 on the protein
level of P-gP and MRP-1 were illustrated. Due to a bigger standard deviation it is hard to
say, if 1 mM glutamate really could decrease the expression of P-gP significantly.
However, 1 mM glutamate with 10 µM MK801 probably had a tendency to decrease the
total P-gP level.
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The expression of the efflux pump MRP-1 seemed to be almost not, or just slightly
influenced by 1 mM glutamate with/without 10 µM MK801 compared to the control.
However, a small decreasing tendency was visible.
Fig. 4.5.2: Influence of 1 mM glutamate with/without 10 µM MK801 on the total protein level of P-gP and
MRP-1. C = Control, G = 1 mM glutamate, M = 1 mM glutamate/10 µM MK801. Values are expressed as
means +/- SEM (n=2).
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Cell-adhesion molecules (ICAM-1, E-Selectin):
Figure 4.5.3 shows the influence of 1 mM glutamate with/without 10 µM MK801 on the
total protein level of ICAM-1 and E-selectin. Thereby, it appeared that 1 mM glutamate
did not influence the protein level of ICAM-1, but in combination with 10 µM MK801 the
protein level has doubled compared to the control values.
No E-selectin was found at all. This indicates that the cells were not induced to an
inflammatory status. For a better demonstration samples positive for E-selectin were
additionally shown.
Fig. 4.5.3: Influence of 1 mM glutamate with/without 10 µM MK801 on the expression of ICAM-1 and E-
selectin. C = Control, G = 1 mM glutamate, M = 1 mM glutamate/10 µM MK801, P = Positive match for E-
selectin. Values are expressed as means +/- SEM (n=2).
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Cyclooxygenases (COX-1, COX-2):
The influence of 1 mM glutamate with/without 10 µM MK801 on cyclooxygenases were
also tested and shown below in figure 4.5.4. 1 mM glutamate seemed to decrease COX-1
expression slightly, whereas it decreased COX-2 expression distinctly. Moreover, it was
quite interesting that 10 µM MK801 seemed to influence protein expression significantly,
both COX-1 as well as COX-2 expression was drastically decreased by this channel
blocker.
Fig. 4.5.4: Influence of 1 mM glutamate with/without 10 µM MK801 on the total protein level of COX-1 and
COX-2. C = Control, G = 1 mM glutamate, M = 1 mM glutamate/10 µM MK801. Values are expressed as
means +/- SEM (n=2).
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5 Discussion
Although diseases such as Alzheimer´s disease, schizophrenia, epilepsy or stroke are
caused by different mechanism they share one common target, the NMDA-receptor
[16].The presence and participation of this glutamate-gated ion channel in major regulatory
mechanisms had also been reported more and more often at the BBB [18, 20, 21].
Therefore it is not astonishing that such pathological conditions must be seen as a critical
event causing a failure of protective and regulative functions at the blood-brain barrier. At
this, not only an increased BBB permeability [18, 20] and a decreased expression of thight
junctions [21] resulting in a BBB disruption. Studies also already showed that
overstimulation of the NMDA-receptor is a possible pathway that lead to an up-regulation
of the ABC-transporter P-gP [25,26] what is a major problem in the therapy of many brain
disorders and the cause of resistance in several kinds of treatment [22, 23].
One main goal of the thesis was to establish a 96-well plate fluorescence method, which
should be used to measure changes in the intracellular calcium level by an activation of the
NMDA receptor in ECV304 cells. Based on data of Kuhlmann et al. [20] who published
already the presence of the NR-1 subunit in cell line ECV304 by immunofluorescence
microscopy and influence of glutamate onto barriers integrity and formation of reactive
oxygen species (ROS), the idea was to measure the influence of NMDAR modulators on
the intracellular calcium level and to link these effects to BBB properties.
In spite of everything, the presence of the NMDA-receptor in cell line ECV304 had to be
verified first, since this was the basic prerequisite for successful subsequent studies,
although Kuhlmann et al. [20] has already shown the presence of NR-1 subunit in cell line
ECV304. However, a recheck was conducted in order to confirm his finding and amend it
with the detection of NR-2A, -2B and -2C subunits also by immunofluorescence
microscopy. To compare our results with the work of Kuhlmann et al. [20], a similar
protocol was used, using methanol to fix and permeabilize the cells. In addition, cells were
alternatively fixed with paraformaldehyde and permeabilized with Triton-X 100. Due to
similar results the images of the methanol protocol were not presented in this thesis. In
order to confirm immunofluorescence images and presence of the NMDAR subunits
western blot analysis for the NMDA-receptor subunits were performed additionally to
check their presence with a second method on the protein level. Interestingly the bands
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which were obtained did not match to the predicted molecular weight of the respective
subunit, but since bands at the same height were always found in the positive controls,
either some sort of decomposition during the assay or unspecific binding of the primary
antibody were assumed. Nearly all subunits showed at least one strong band at an
appropriate molecular weight, which could be compared with the positive control. Only
those samples of NR-2C subunits showed just a slightly visible band what could be
compared with a strong band of the positive control. Somehow this outcome of a low
visible NR-2C band did not match to the intense fluorescence images of the
immunofluorescence microscopy, unlike it was possible for the other subunits. However,
although polyclonal antibodies were purchased, the strong bands which were seen in the
western blot analysis were assumed to be related to NMDA-sequence-binding.
Since the presence of the NMDA-receptor was more or less shown, it was focused onto the
main goal of this thesis to establish a 96-well plate fluorescence method for measuring the
change of the intracellular calcium level. Already the first few experiments showed
interesting results, since choosing of an adequate multiplate reader was of high importance.
Hardly any differences could be seen or conclusions made from the results obtained with
the Polarstar galaxy microplate reader except a concentration-dependent effect of the
fluorescent dye with the positive control Ionomycin and that an uptake of the fluorescence-
dye Fluo3-AM into the cells proceeds. Compared to both other used multiplate readers, the
Polastar galaxy can not keep up with, probably because of its technical equipment. On the
other hand, measurements with the two different Tecan multiplate readers revealed better
and also more useful data. Even kinetic-like experiments were tried to perform, to obtain
information from the change of intracellular calcium level in the early phases. However,
although all measured pairs of rows were treated the same, the factor „time“, what was
needed between two pairs of rows, seems to have an important influence which adulterate
the values and the intracellular calcium level. Due to this experience kinetic-like
experiments were stopped, since those results were quite questionable.
Steady-state measuring showed stable and more interesting results after a capable protocol
was set up by checking out and changing different parameters (NBS vs. Albumin, HBSS
with/without Mg2+, loading time of fluorescence-dye-solution, use of Probenecid, Fluo3-
AM vs. Calcium-Green-AM,...). An increasing intracellular calcium level was always
assumed after activating the NMDA receptor with either different concentrations of
glutamate or NMDA, but somehow our established 96-well fluorescence measuring
method was not able to show such effects. A few similar methods with other cell lines exist
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[44, 45, 46] that presented results where the intracellular calcium level increases after
glutamate or NMDA stimulation, and even Kuhlmann et al. [20] showed that this should be
possible with ECV304 cells after glutamate addition. However, somehow it seems that
influxes into the cells by other channels and/or maybe a release from intracellular stores
were seen everytime, whereby the increased intracellular calcium level of the control could
be taken as best example for this effect. Since those values were not stimulated by any
substance the measured increased intracellular calcium level were quite interesting. In
contrast to this effect, concentration-dependent changes in intracellular calcium level of
NMDA and also once with glutamate were obtained. Though here the calcium level after
NMDA application did not increase, it rather decreased. This maybe could be related to
some sort of counter-regulations by efflux-pumps like the Na+/Ca2+-exchanger or the
ubiquitous PMCA, or an induced uptake into the internal stores [56].
Although the effect of a decreased intracellular calcium level caused by NMDA is quite
strange, the NMDA-receptor blocker MK801 was able to show an effect that was assumed
prior to our experiments. By the binding of MK801 at the PCP binding site, inside of the
NMDA receptor channel influx of calcium through the channel is prevented. This effect of
a decreased intracellular calcium level was seen in a concentration-dependent manner,
whereby a significant effect was seen with 100 µM MK801. Interestingly, this effect was
only seen in Mg2+-free solution. In this regard, in a recent publication where the influence
of different NMDAR-subunit compositions onto the calcium influx was investigated used
also only Mg2+-free solution to assess their effects [57]. Maybe Mg2+-free solutions are
necessary to detect the effects in a more significant manner since present Mg2+ possible
would lead after opening the channel to a subsequent closing. Furthermore, it could be
possible that no sufficient depolarization was reached to alleviate the Mg2+-block in a
voltage-dependent manner in normal HBSS (8264), by what good effects were only seen in
Mg2+-free solutions. Therefore calcium measurements over the NMDA-receptor were
normally carried out in Mg2+-free solutions to reach a maximal calcium response [47] and
moreover studies already revealed that the depolarization can vary depending on the
formation of the NMDA-receptor subunits [48]. If in retrospect the NMDA-receptor turns
still out to be not functional, another alternative could be a block of a different Ca2+-
increasing mechanism by MK801. Diverse dissociative anaesthetics like phencyclidine or
ketamine already revealed that NMDA receptors and nicotinic acetylcholine receptors,
although they are not structurally related, share certain pharmacological properties [49].
Referring to this, MK801 could also inhibit both receptors by binding to different domains
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than that for each specific neurotransmitter and moreover it is suggested that this inhibition
may not simply be the result of a steric blockade of open-channel acetylcholine receptors
[50]. Therefore, to test a possible contribution of acetylcholine-receptors the influence of
ACh on the intracellular calcium level in ECV304 cells was tested. The outcome of these
experiments in solutions with/without Mg2+ revealed that different concentrations of ACh
had no effect on the intracellular calcium level in our model, moreover the decreased
intracellular calcium level of MK801 was only seen in Mg2+-free medium. However, ACh
is a very unstable substance, thus other ACh-receptor agonists as well as antagonists
should be tested in order to check the hypothesis that ACh-receptors may play an important
role in ECV304 cells for the calcium level.
Since the controls had always one of the highest intracellular calcium levels, the influence
of a different possible activated calcium channel was tested. Evidence of beneficial effects
in reducing the rate of stroke in hypertensive patients by calcium channel antagonists were
reported [51]. As a commonly used L-type-calcium channel blocker acting in the periphery
and not in the CNS Verapamil was tested. A pre-test already showed that Verapamil is able
to keep the intracellular calcium level lower compared to the control. Thus, the influence
of this L-type calcium channel agonist with/without the antagonist was tested in solutions
with/without Mg2+. Verapamil was able to keep the intracellular calcium level lower in
solutions with as well as without Mg2+ compared to the control or the also tested L-type
channel agonist (S)-(-)-BayK8664. Thus, this partially inhibition of an increasing calcium
seems not to be as Mg2+-dependent as it was in the MK801 experiments and could be
another hint for the cause of the increased control-values due to an maybe always activated
voltage-gated calcium channel. Moreover, concentration-dependent effects of the L-type
calcium channel activator (S)-(-)-BayK 8664 were found. Curve progressions similar to the
NMDA-experiments were recorded for BayK 8664. This substance was also able to
influence the intracellular calcium level, whereby a concentration of 100 µM had nearly no
effect. If we abstract away the fact that calcium channel activators normally increase the
level of intracellular calcium, it was quite interesting to see that 100 µM BayK 8664 seems
to be able to completely nullify the effects that were normally seen by the control.
Although an enantiomere pure (S)-(-)-BayK 8664 was obtained, what is said to be an L-
type-channel activator [52], the outcome fits more to the results of an antagonist. Only
considering the data, it could be speculated that maybe (R)-(+)-BayK 8664, a L-type-
calcium channel blocker was insteadly used. However, since similar effects were already
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seen in the NMDA-experiments, again some sort of counter-regulation should not be
excluded during the course of the experiments [56].
Due to those outcomes we also tested for possible counter-regulations or a possible release
of internal stores after Ca2+-channel stimulation. Since some studies assume that the efflux
of calcium is mainly caused by PMCA in ECV304 cells [53], it was decided to focus on
PMCA and not on Na+/Ca2+-exchanger. Ryanodine, a SERCA-inactivator and methyl-ß-
cyclodextrine, a dextrine that removes the PMCA out of the plasma membrane, were tested
in order to see their influence on the intracellular calcium level. Based on the obtained
results, tendencies of a lowered intracellular calcium level were seen in the ryanodine
treated cells. Addition of ryanodine maybe resulted in a higher intracellular calcium level,
whereon PMCAs were probably activated and subsequently calcium in the cells was
reduced. Methyl-ß-cyclodextrine had a big impact on the basic fluorescence. After PMCA
were removed from the surface of the membrane, probably the calcium equilibrium was
disturbed and just less calcium could be transported outside of the cells. The basic
fluorescence increased ~2-3 times in comparison to observed basic fluorescence in all
other experiments. This effect maybe indicated the importance and activity of the PMCA
in ECV304 cells and it moreover explains, why lower intracellular calcium concentrations
were observed after stimulation with NMDA or BayK 8664, since this stimulation maybe
induced a higher activation of the efflux-transporter. However, it has to be mentioned that
the treatment with methyl-ß-cyclodextrine can also lead to a loss of cholesterol in the
membrane and thus maybe result in a generally disintegrated membrane and an imbalance
in the intracellular calcium level. In order to investigate this in more detail, more specific
peptides blocking PMCA should be tried out in following experiments. Despite of this, the
methyl-ß-cyclodextrine experiment confirmed the suitability of the Calcium-assay since
the enormous increase of intracellular calcium was able to be detected.
Due to the questionable outcomes, the high concentrations that were needed to see effects
and the differing effects of NMDA compared with glutamate, a re-check for the NMDA-
receptor presence was made, where cells for immunofluorescence microscopic images
were not permeabilized. In general many studies where a participation of the NMDA
receptor was assumed, the channel was either detected by western blot analysis [18, 21], or
immunofluorescence confocal microscopy [20]. However, most reports did not show the
molecular weight of the NMDA receptor bands in their western blots, furthermore
NMDAR subunits could probably be detected, but if the target is really expressed on the
surface could not be analysed by western blots. Results of immunofluorescence images are
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also somehow questionable, when cells had to be permeabilized so the primary antibody
can bind to a sequence that is located in the cytoplasm. As seen in our results, the
permeabilized images suggested also a high expression of the subunits in our cell line, but
as seen in non-permeabilized ECV304 cells, nearly no binding of the primary antibody
could be seen. Thus, although the primary antibodies target extracellular domains of the
NMDA-receptor nearly no or just a small amounts of NMDA-receptors could be found on
the surface. In general, the presence of the NMDA-receptor on the BBB is a very
controversially discussed topic. Some reseachers showed the presence of this target [18] on
the BBB and others, who hypothesize no expression [54]. Another possibility why hardly
any NMDA-receptor subunits were found on the surface of ECV304 cells could be due to
an incomplete formation of a functional receptor. Studies already revealed that the LIVBP-
domain of the NMDA receptor must interact with other regions of the receptor to form a
stable subunit association [17].
Since the functionality of the NMDA-receptor on ECV304 cells became from experiment
to experiment more unclear, it was decided to test the influence of 1 mM glutamate
with/without 10 µM MK801 on another parameter, namely the transendothelial electrical
resistance (TEER). This is a commonly used method to check the integrity of BBB layers.
Previous publications showed a decrease of electrical resistance after application on
glutamate which was blocked by addition of MK801. Thus these effects were mostly
attributed to an activation of NMDA receptors [18, 20]. Generally glutamate (probably to
stimulate “normal” pathologiacal conditions) was used for most NMDA receptor
experiments [20, 21, 26, 55], instead of the more specific NMDA [18, 25]. Effects of other
pathways like metabotropic glutamate receptors that could be activated by glutamate were
mostly not considered there. However, since the functionality of the NMDA-receptor is
more or less disputable in our ECV304 cell line, the loss in the BBB integrity caused by
glutamate maybe approved that also other pathways could play an important role in those
effects, but would confirm data of already published reports.
The cells of those TEER-experiments were lysed and western blot analysis were performed
in order to investigate changes in protein expressions additionally. Although, as mentioned
before, ECV304 cells seems not to express the NMDA-receptor highly on the surface of
the cells, the influence of the TEER-experiments were quite interesting and even the
outcome fits to studies who assumed NMDA-receptor presence and function on their cell
line [18, 20]. Since effects also on the protein expression level were supposed to be
mediated by the NMDA-receptor, the influence of glutamate with/without MK801 on the
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expression on specific proteins, which was also already shown in other studies [21, 25],
was additionally investigated. Our goal was to test for some of those published results and
compare them with our results.
Treatment with 1 mM glutamate resulted in a decrease in the total protein level of
Occludin what even could not be prevented by the NMDA-receptor antagonist MK801.
Such an effect was already shown before. In this regard, it was assumed that changes in
Occludin-phosphorylations were responsible for the protective effect of MK801 and not a
reduced decrease of the protein level [21]. Although it was said that the effects of
glutamate on tight junctions proteins have the earliest and most dramatic effects on
Occludin [21], the influence on ZO-1 was also observed. The outcomes showed that
glutamate really had no big effect on the protein level of ZO-1, it moreover seemed to
increase it slightly. However, somehow glutamate in combination with MK801 seemed to
induce ZO-1 expression. This could maybe interpreted as a counter-regulation due to the
loss of the total protein level of Occludin, perhaps to bind to or tighten the remaining
Occludin proteins to the actin cytoskeleton.
Stimulation with glutamate is said to increase the P-gP expression over an NMDA-receptor
mechanism what could be attenuated by MK801 [25, 26]. Interestingly, exactly an opposite
effect was observed in our experiments, where the expression due to glutamate
with/without MK801 stimulation seems to decrease P-gP expression. Because of the bigger
standard deviation it is possible that those values just changed slightly or nearly not at all it
was observed by the bars only. This fits to the hypothesis, where the expression of P-gP is
regulated by a NMDA-mechanism, if our ECV304 cells really had no functional NMDA-
receptor. However, in this context it has also to be mentioned that the analysed P-gP band
in the western blotting was at 95 kDa, whereas the expected band should be at app. 170
kDa. Thus, these results should only be considered as preliminary. The influence of
glutamate with/without MK801 on another efflux pump MRP-1 was also tested. As a result
of the outcomes we could say that MRP-1 was probably not affected in our model.
Also the influence of 1 mM glutamate with/without 100 µM MK801 on the expression of
adhesion molecules was tested. Compared to the control, 1 mM glutamate had no influence
on the expression of ICAM-1. However, 1 mM glutamate with 100 µM MK801 drastically
increased the expression what is normally seen from cytokine stimulation. This observation
could link recently published results that the NMDAR subunit NR1 should play an
important role in the transmigration of monocytes across the BBB during conditions of
multiple sclerosis [58] However, E-selectine expression was not induced by glutamate
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plus/minus M801, therefore inflammation caused by cytokines could be excluded in this
case, since E-selectine is only expressed in endothelial cells which were activated by
cytokines. This was also confirmed for ECV304 cells in our lab previously.
Since there were also studies which assumed an induction of P-gP by a glutamate/NMDA-
receptor/COX-2 signalling pathway [25], the influence of glutamate with/without MK801
on the protein expression of cyclooxygenases were tested. Interestingly, we could not
observe any induction of cyclooxygenases, rather the protein level of COX-1 was slightly
and of COX-2 more drastically decreased by 1 mM glutamate. However, 1 mM glutamate
with 100 µM MK801 drastically decreased the protein expression, by what an convertion
of arachidonic acid to prostaglandine H2 is probably suppressed. In contrast to this, Bauer
et al. proposed no regulation of COX enzymes on the expression level, but changes on the
functional level [25].
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6 Conclusions
• The presence of NR-1, -2A, -2B and -2C subunits could be shown in ECV304 cells by
methods as western blot analysis and immunofluorescence microscopy. An expression
of those targets was mostly found in the cytoplasm and not on the cell surface whereby
the functionality is still disputable.
• The major goal of this thesis was to develop a fluorescence method for measuring the
changes in the intracellular calcium level. Therefore, a solid working protocol was
successfully established within this diploma thesis and was then used for investigations
with regard to the NMDAR. Applications of NMDAR modulators (NMDA, glutamate,
MK801, D-APV) as well as other calcium modulators as e.g. BayK8664 and
Verapamil provided interesting insights in the regulation of the intracellular calcium
level of ECV304 cells, which partly confirmed known literature, but would also need
further investigations to clarify observed effects in detail.
• The influence of glutamate on the transendothelial electrical resistance, a parameter for
BBBs integrity, was moreover assessed. In concordance to literature, it was able to
show that 1 mM glutamate decreased the integrity of the blood-brain barrier model,
which was blocked by NMDAR antagonist 10 µM MK801, indicating a possible role
of the NMDAR during this process. Furthermore, changes of the expression of several
proteins as tight junctional proteins Occludin, ZO-1 and Claudin-5, as well as ICAM-1
and P-gP were observed.
• However, since the NMDA-receptor seemed to be expressed in the cytoplasm mainly,
these effects as well as changes of the intracellular calcium level by MK801 could
probably be caused by other signalling pathways than primarily assumed. Thus, in
conclusion the presented data showed effects of NMDAR-modulators on the blood-
brain barrier in vitro model based on ECV304 cells, but did not confirm a direct link to
a typically functional NMDA-receptor.
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8 Abbreviations
ABC-transporter ATP-binding casette transporter
AC Astrocytes
ACh Acetylcholine
ACM Astrocyte conditioned medium
AJ Adherens junctions
AP Alkaline phosphatase
APS Ammonium persulfate
AQP4 Aquaporine 4
BBB Blood brain barrier
BMEC Brain microvascular endothelial cells
BSA Bovine standard albumin
CIF Calcium-influx factor
CNS Central nervous system
COX Cycooxygenase
D-APV 2-amino-5-phosphonopentanoic acid
DMSO Dimethylsolfoxid
DTT Dithiothreitol
EC Endothelial cells
ER Endoplasmatic reticulum
EtOH Ethanol
FITC Fluorescin isothiocyanate
GGTP ?????????????????????????
Ham´s F12 Ham reg. Nutrients mixture F12
126
HBSS Hank´s balanced salt solution
Hepes 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
HRP Horseradish peroxidase
ICAM Intracellular adhesion molecule
IMDM Iscove´s modified Dulbeccoßs medium
InsP3 Inositol 1, 4, 5, triphosphate
JAM Junctional adhesion molecule
LAF Laminar air flow
MAGUK Membrane associated guanulate kinase
MDR Multidrug-resistance
MeOH Methanol
MK801 Dizocilpine
MRP Multidrug resistance associated protein
NCS Newborn calf serum
NMDA N-methyl-D-aspartaic acid
NMDAR NMDA-receptor
OAT Organic anion transporter
PBMEC Porcine brain microvascular endothelial cells
PC Pericycte
P-FA Paraformaldehyde
P-gP P-glycoproteine
PMCA Plasma membrande Ca2+-ATPase
PVDF Polyvinylidenefluoride
ROC Receptor operated channels
RT Room temperature
RYR Ryanodine receptor
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SDS Sodium dodecyl sulfate
SDS-Page Sodiumdodecylsulfate polyacrylamid gel electrophoresis
SERCA Sarco/endoplasmatic reticulum Ca2+-ATPase
SOC Store operated channels
SR Sarcoplasmatic reticulum
TBS Tween buffered saline
TEER Transendothelial electrical resistance
TEMED N, N, N´, N´-tetramethylethylene diamine
TJ Thight junction
TRIS Tris(hydroxymethyl)-aminomethane
VE-cadherin Vascular endothelial cadherin
VOC Voltage operated channels
Vs. versus
ZO Zonula occludens
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